Microorganism-derived transglutaminase fusion product

The microbial-derived transglutaminase fusion addresses the inefficiencies in ADC production by enabling specific antibody modification without deglycosylation, improving efficiency and reducing costs through controlled site-specific binding and reduced self-modification.

WO2024232299A1PCT designated stage expired Publication Date: 2024-11-14KYUSHU UNIV

Patent Information

Application Number
PCT/JP2024/016451
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-08
Filing Date
2024-04-26
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current methods for producing antibody-drug conjugates (ADCs) using microbial transglutaminase (MTG) face challenges such as low modification efficiency, difficulty in controlling the modification site, and the need for deglycosylation and additional purification steps, which increase time and cost.

Method used

Development of a microbial-derived transglutaminase fusion (MTG fusion) that combines an active MTG precursor with a protein G mutant, allowing specific modification of lysine residues on antibodies without deglycosylation, and optimization of the fusion's structure to enhance modification efficiency and avoid self-modification issues.

Benefits of technology

The MTG fusion enables efficient, site-specific modification of antibodies, reducing the complexity and cost of ADC production while maintaining high cross-linking activity, allowing for the production of homogeneous antibody-substrate complexes with controlled modification positions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024016451_14112024_PF_FP_ABST
    Figure JP2024016451_14112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided is a method for producing a highly homogeneous antibody substrate conjugate, the method being capable of controlling the drug-antibody binding ratio and the modification position on an antibody. This method uses an enzyme conjugate capable of improving antibody modification efficiency and controlling the antibody modification site. This enzyme conjugate was developed using an active microorganism-derived transglutaminase precursor. Provided is a microorganism-derived transglutaminase fusion product obtained by fusion of an active microorganism-derived transglutaminase precursor and an antibody-binding protein.
Need to check novelty before this filing date? Find Prior Art

Description

Microbial transglutaminase fusion

[0001] The present invention relates to a microbial transglutaminase fusion product, an antibody modifying agent containing the same, and a method for producing an antibody-substrate complex using the antibody modifying agent.

[0002] Antibody drugs are therapeutic drugs that use antibodies that specifically bind to a given disease-related molecule, and have become a central part of biopharmaceuticals in recent years. However, although antibodies have extremely high specificity for antigens, they generally have lower antitumor activity on their own compared to conventional small molecule drugs. On the other hand, small molecule drugs have high antitumor activity, but are prone to side effects due to their low cell specificity and selectivity, making them difficult to use as drugs on their own.

[0003] As a means to solve the problems of antibody drugs and small molecule drugs, antibody-drug conjugates (ADCs), which combine the specificity of antibodies with the efficacy of small molecule drugs, are attracting attention as next-generation antibody drugs. ADCs are drugs in which a small molecule drug is attached to an antibody via a linker. By utilizing the antigen specificity of antibodies, small molecule drugs can be delivered specifically and selectively to target cells, which enables a more powerful and broader therapeutic range than existing chemotherapy agents, and also reduces the side effects of small molecule drugs.

[0004] Chemical and enzymatic methods are known for producing ADCs. Chemical methods involve attaching a drug to lysine or cysteine ​​residues on an antibody via a chemically reactive group. However, the large number of lysine residues in an antibody makes it difficult to control the drug binding site. Therefore, enzymatic methods, which are highly specific and can catalyze reactions under mild conditions, are currently being actively researched, and various ADC production methods using enzymes have been reported (Non-Patent Documents 1-3). Among these, the enzymatic method that has attracted the most attention in recent years is the method using microbial transglutaminase (MTG) (Patent Document 1, Non-Patent Document 4).

[0005] Transglutaminases (TGases) are found in many organisms, including microorganisms, animals, and plants, and play a variety of roles, including regulating gene expression, blood coagulation, and skin formation (Non-Patent Document 5). Among these, a TGase isolated from the actinomycete Streptomyces mobaraensis (Non-Patent Document 6) is called MTG, and can be mass-produced and exhibits high cross-linking activity. Furthermore, other TGases lack the cofactor Ca, which is required for catalytic activity. 2+ However, MTG does not require this step. As a result, MTG has been used in recent years to produce ADCs with uniform structure as an easy-to-operate TGase.

[0006] For the binding of IgG to drugs using MTG, IgG was deglycosylated and the exposed glutamine residue at position 295 (Q 295 A method for introducing a drug into a soluble form of ...

[0007] MTG is expressed in microorganisms as an inactive precursor (Figure 2A). The N-terminal propeptide region is cleaved and removed by the protease activity of S. mobaraensis itself, resulting in the mature, active form (Figure 2B). The mature form of MTG is required for the production of ADCs using MTG. However, direct expression of the mature form in an E. coli expression system resulted in the formation of insoluble inclusion bodies, making it necessary to coexpress a recombinant MTG precursor with a protease. However, this expression system could potentially inactivate MTG through partial hydrolysis by the protease. Furthermore, a purification step to completely remove the propeptide and protease after expression was required. Therefore, the preparation of active MTG required additional steps, increased labor, and increased costs.

[0008] As a method for solving the above problems, Patent Document 2 discloses an MTG mutant developed by the present inventors. Although the MTG mutant is a precursor, it has catalytic activity equivalent to that of the mature form, and it also has the advantage of being able to be mass-produced in an Escherichia coli expression system. However, the deglycosylation treatment of the antibody is still required, and the modification efficiency of the MTG mutant on untreated native antibodies is extremely low, which remains a problem.

[0009] WO2019 / 107288WO2018 / 004014

[0010] Grunewald J., et al., 2015, Bioconjugate Chem., 26: 2554-2562Sato S., et al., 2020, Bioconjugate Chem., 31: 1417-1424Lee MD, et al., 2019, Bioconjugate Chem., 30: 2539-2543Schneider H., et al., 2020, Anal. Biochem., 595: 113615Chen JSK & Mehta K., 1999, Int. J. Biochem. Cell Biol., 31: 817-836Ando H., et al., 1989, J. Agric. Food Chem., 53 (10): 2613-2617Dennler P., et al., 2014, Bioconjugate Chem., 25: 569-578

[0011] An object of the present invention is to develop an enzyme complex that utilizes the MTG mutants developed by the present inventors, which allows for improved antibody modification efficiency and control of the modification site.

[0012] Another object of the present invention is to provide a method for producing ADCs with a uniform structure using the newly developed enzyme complex, which is simple and enables control of the modification site on an antibody.

[0013] The difficulty in modifying antibodies with MTG is thought to be due to the low reactivity of MTG with lysine and glutamine residues in IgG, as described by Mindt et al. (Mindt TL, et al., 2008, Bioconjugate Chem., 19: 271-278).

[0014] Therefore, the present inventors developed an MTG fusion by fusing the MTG mutant (active MTG precursor: active ProMTG) with protein G (pG), which specifically binds to antibodies, to bring the MTG mutant into close proximity with the antibody. It was found that this MTG fusion can selectively and efficiently modify only the lysine residue at position 65 of the IgG heavy chain with a substrate molecule containing a glutamine residue, without requiring deglycosylation. However, this newly developed method also revealed new problems with MTG fusions, such as the possibility of aggregate formation between the antibody and the MTG fusion, or the self-modification of the lysine residues of the MTG fusion itself when a substrate molecule containing glutamine residues is used to modify the antibody.

[0015] To address these issues, the present inventors further improved MTG fusions. First, they focused on the fact that aggregation formation is promoted by binding of wild-type pG to the antibody Fc and Fab regions, and the presence of MTG-reactive lysine residues in the pG sequence. Therefore, they introduced mutations into the Fc-binding region or Fab-binding region of wild-type pG to create MTG fusions containing pG mutants that specifically bind to either the Fc or Fab region of an antibody. As a result, they successfully resolved all of the aforementioned new problems of MTG fusions. Furthermore, they found that a new MTG fusion in which the order of active ProMTG and pG is reversed in the MTG fusion specifically recognizes and efficiently modifies only the lysine residue at position 225 of the IgG heavy chain. Furthermore, they found that the efficiency of IgG modification was enhanced when the order of active ProMTG and pG was reversed via a charged linker. Based on these new findings, the present invention provides the following:

[0016] (1) A microbial transglutaminase fusion (MTG fusion) comprising an activated microbial transglutaminase precursor and an antibody-binding protein, wherein the activated microbial transglutaminase precursor comprises a mutant propeptide region in which at least one tyrosine residue and a lysine residue, at least one asparagine residue and a lysine residue, or at least one asparagine residue, at least one tyrosine residue and a lysine residue in the propeptide region of the microbial transglutaminase precursor are substituted with other amino acid residues. (2) The MTG fusion according to (1), wherein the microbial transglutaminase precursor has an amino acid sequence selected from the group consisting of any one of the following: (a) to (c) (a) the amino acid sequence shown in SEQ ID NO: 1, (b) an amino acid sequence in which one or more amino acid residues have been added, deleted, and / or substituted at positions other than 10, 12, 16, 25, and 27 in the amino acid sequence shown in SEQ ID NO: 1, (c) an amino acid sequence having 90% or more amino acid identity with the amino acid sequence shown in SEQ ID NO: 1, (3) the MTG fusion according to (2), in which the substituted lysine residue is at position 10 in the amino acid sequence shown in SEQ ID NO: 1, the tyrosine residue is at positions 12 and 16 in the amino acid sequence shown in SEQ ID NO: 1, and the asparagine residue is at positions 25 and 27 in the amino acid sequence shown in SEQ ID NO: 1, or residues at corresponding positions in the amino acid residues of (b) or (c). (4) the MTG fusion according to any of (1) to (3), in which the antibody-binding protein is Fab-binding protein G that has lost its ability to bind to the Fc of IgG. (5) The MTG fusion according to (4), wherein the Fab-binding protein G further comprises amino acid substitutions at all lysine and glutamine residues in the Fab-binding region. (6) The MTG fusion according to (5), wherein the Fab-binding region comprises the amino acid sequence set forth in SEQ ID NO: 3. (7) The MTG fusion according to any of (1) to (3), wherein the antibody-binding protein is Fc-binding protein G that has lost the ability to bind to Fab in IgG. (8) The MTG fusion according to (7), wherein the Fc-binding protein G further comprises amino acid substitutions at all or some of the lysine residues in the Fc-binding region.(9) The MTG fusion according to (8), wherein the Fc-binding region comprises the amino acid sequence shown in SEQ ID NO: 5. (10) The MTG fusion according to any one of (1) to (9), comprising the activated microbial transglutaminase precursor at the N-terminus and the antibody-binding protein at the C-terminus. (11) The MTG fusion according to any one of (1) to (9), comprising the activated microbial transglutaminase precursor at the C-terminus and the antibody-binding protein at the N-terminus. (12) The MTG fusion according to any one of (1) to (11), wherein the activated microbial transglutaminase precursor and the antibody-binding protein are fused via a linker consisting of a peptide chain. (13) The MTG fusion according to (12), wherein the linker comprises a negatively charged amino acid residue. (14) A nucleic acid encoding the MTG fusion according to any one of (1) to (13). (15) A vector comprising the nucleic acid according to (14). (16) A transformant comprising the vector according to (15). (17) A method for producing an MTG fusion, comprising: a mutation introduction step of introducing mutations into codons encoding at least one tyrosine residue and a lysine residue, at least one asparagine residue and a lysine residue, or at least one asparagine residue, at least one tyrosine residue and a lysine residue in the propeptide region of a nucleic acid fragment encoding ProMTG, substituting them with other amino acid residues; a ligation step of ligating a nucleic acid fragment encoding ProMTG with a nucleic acid fragment encoding an antibody-binding protein to prepare a TG fusion gene encoding an MTG fusion; and an expression step of expressing the TG fusion gene in a host cell. (18) An antibody modifying agent comprising the MTG fusion of any of (1) to (13), which crosslinks a substrate molecule containing a glutamine residue to an antibody. (19) An antibody modifying agent comprising the MTG fusion of (10), which crosslinks a substrate molecule containing a glutamine residue to the lysine residue at position 65 of an antibody. (20) An antibody modifying agent comprising the MTG fusion protein according to (11), which crosslinks a substrate molecule containing a glutamine residue to the lysine residue at position 225 of an antibody. (21) The antibody modifying agent according to any one of (18) to (20), wherein the substrate molecule contains an azide group, an alkynyl group, or a cycloalkynyl group.(22) A combined antibody modifying agent comprising two or more different antibody modifying agents according to (18) to (21). (23) A method for producing an antibody-substrate conjugate, comprising: an antibody binding step of mixing an antibody and any one of the antibody modifying agents according to (17) to (21) and binding an MTG fusion contained in the antibody modifying agent to the antibody to prepare an antibody-enzyme conjugate; a crosslinking step of mixing the antibody-enzyme conjugate with a substrate molecule containing a glutamine residue and crosslinking the substrate molecule to the antibody to prepare an enzyme-antibody substrate conjugate; and an enzyme separation step of separating the MTG fusion from the enzyme-antibody substrate conjugate. (24) The production method according to (23), comprising a substrate molecule modification step of modifying the substrate molecule with a glutamine residue or a peptide fragment containing same prior to the crosslinking step. (25) A method for producing an antibody-substrate complex, comprising: an antibody binding step of mixing an antibody and the combined antibody modifying agent described in (22) and binding each MTG fusion contained in the combined antibody modifying agent to the antibody to prepare an antibody-enzyme complex; a crosslinking step of mixing the antibody-enzyme complex with two or more substrate molecules each containing a lysine residue and a glutamine residue and crosslinking the substrate molecule to the antibody site to prepare an enzyme-antibody substrate complex; and an enzyme separation step of separating the MTG fusion from the enzyme-antibody substrate complex. (26) The method according to (25), further comprising, prior to the crosslinking step, a substrate molecule modification step of modifying the substrate molecule with a lysine residue and a glutamine residue or a peptide fragment containing each amino acid residue. (27) The method according to any one of (23) to (26), wherein the substrate molecule comprises a low molecular weight compound. (28) An antibody-substrate complex in which a substrate molecule is crosslinked to the lysine residue at position 65 of an IgG heavy chain. (29) An antibody-substrate complex in which a substrate molecule is crosslinked to the lysine residue at position 225 of an IgG heavy chain. This specification includes the disclosure of Japanese Patent Application No. 2023-076790, from which the present application claims priority.

[0017] The MTG fusion of the present invention can provide an antibody modifying agent that can control the modification site on the antibody that crosslinks the substrate molecule.

[0018] The antibody modifying agent of the present invention allows crosslinking of substrate molecules to specific lysine residues of antibodies.

[0019] The combined antibody modifying agents of the present invention allow substrate molecules to be crosslinked to specific lysine and glutamine residues of an antibody.

[0020] According to the method for producing an antibody-substrate conjugate of the present invention, it is possible to easily produce a highly uniform antibody-substrate conjugate in which the modification position on the antibody can be controlled.

[0021]

[0023] Figure 1 is a schematic diagram of a microbial transglutaminase fusion of the present invention. A and B both represent the microbial transglutaminase fusions used in the Examples herein, with A representing Pro(K10R / Y12A)MTG-(G4S)3-pG and B representing pG-G4S-Pro(K10R / Y12A)MTG. This figure shows the precursor (A: ProMTG), mature form (B: mature MTG), and active precursor (C: active ProMTG) of microbial transglutaminase. In the precursor (A), the propeptide region inhibits the activity of the mature MTG region. In the active precursor (C), the introduction of a mutation into the propeptide region (represented by two black lines in the figure) inhibits the inhibitory effect of the propeptide region, resulting in an active precursor. This figure shows the results of SDS-PAGE (top) and fluorescence imaging (bottom) showing the crosslinking activity of Q substrate peptides Pro(K10R / Y12A)MTG-(G4S)3-pG and pG-G4S-Pro(K10R / Y12A)MTG to trastuzumab (IgG). In the figure, ** indicates the IgG heavy chain, and * indicates the IgG light chain. The arrow indicates the position of Pro(K10R / Y12A)MTG, the black arrowhead indicates the position of Pro(K10R / Y12A)MTG-(G4S)3-pG, and the white arrowhead indicates the position of pG-G4S-Pro(K10R / Y12A)MTG. A: Pro(K10R / Y12A)MTG-(G4S)3-pZ Ca2+Figure 1 shows the results of SDS-PAGE (left column) and fluorescence imaging (right column) showing the crosslinking activity of Q substrate peptides to Trastuzumab (IgG) using A: Pro(K10R / Y12A)MTG-(G4S)3-pZ (ΔK), and B: Pro(K10R / Y12A)MTG-(G4S)3-pZ (ΔK, alkaline stabilized). In the figure, ** indicates the position of the IgG heavy chain, and * indicates the position of the IgG light chain. The arrows indicate Pro(K10R / Y12A)MTG-(G4S)3-pZ. Ca2+The arrowhead indicates the position of Pro(K10R / Y12A)MTG-(G4S)3-pZ (ΔK, alkaline stabilized). This is a chromatogram showing the separation of the heavy chain of an antibody modified with Q substrate by Pro(K10R / Y12A)MTG-(G4S)3-pG and the heavy chain of an unmodified antibody by reverse-phase HPLC. In the figure, the peak indicated by a represents the Q substrate TAMRA-YPLQMRG-NH2, the peak indicated by b represents the MTG fusion protein of the present invention, Pro(K10R / Y12A)MTG-(G4S)3-pG, the peak indicated by c represents the light chain of Trastuzumab (IgG), the peak indicated by d represents the unmodified heavy chain of Trastuzumab (IgG), and the peak indicated by e represents the Q substrate-modified heavy chain of Trastuzumab (IgG). Figure 1 shows a comparison of reverse-phase HPLC chromatograms of heavy chain fragment peptides from a Q substrate-modified antibody with Pro(K10R / Y12A)MTG-(G4S)3-pG (derived from peak e in Figure 5 ) and unmodified antibody heavy chain fragment peptides (derived from peak d in Figure 5 ). In the figure, the arrow indicates the peak observed only in the Q substrate-modified heavy chain fragment peptide. Figure 2 shows an evaluation of aggregation formation between the modified MTG fusion protein Pro(K10R / Y12A)MTG-(G4S)3-pG (Fab-ΔKQ) and an antibody. Figure 3 shows an evaluation of the crosslinking activity of the modified MTG fusion protein Pro(K10R / Y12A)MTG-(G4S)3-pG (Fab-ΔKQ). Figure 1 shows the results of SDS-PAGE, and Figure 2 shows a fluorescence image. In the figure, ** indicates the position of the IgG heavy chain, and * indicates the position of the IgG light chain. The arrowhead indicates the position of Pro(K10R / Y12A)MTG-(G4S)3-pG (Fab-ΔKQ). This figure shows a comparison of reverse-phase HPLC chromatograms of the heavy chain fragment peptide of a Q substrate-modified antibody with pG(Fab-ΔKQ)-G4S-Pro(K10R / Y12A)MTG and the heavy chain fragment peptide of an unmodified antibody. The arrow in the figure corresponds to the position of the peak derived from K65 indicated by the arrow in Figure 6, and the two arrowheads indicate peaks observed only in the Q substrate-modified heavy chain fragment peptide. This figure shows CLSM images of SK-BR-3 cells. The upper row, labeled A to G, shows DIC images, and the lower row, labeled a to g, shows TAMRA-YPLQMRG-NH 2 The fluorescent images shown are from the TAMRA-FQ system. The upper and lower images with the same upper and lower case letters represent the same field of view.

[0022] 1. Microbial Transglutaminase Fusion 1-1. Overview A first aspect of the present invention is a microbial transglutaminase fusion. The microbial transglutaminase fusion of the present invention (often referred to herein as an "MTG fusion") is a fusion protein comprising a cross-linking catalytic domain consisting of a microbial transglutaminase and an antibody-binding domain consisting of an antibody-binding protein. The MTG fusion of the present invention has catalytic activity that cross-links substrate molecules to specific amino acid residues of an antibody and can function as an active ingredient of an antibody modifying agent.

[0023] 1-2. Definition of Terms The following terms used in this specification are defined. "Fusion protein" refers to a polypeptide chain containing multiple peptide domains of different origins linked in a linear chain. In this specification, this term refers to an artificial polypeptide encoded by a recombinant gene artificially produced using genetic engineering technology.

[0024] As used herein, the term "cross-linking catalytic domain" refers to a peptide domain having the enzymatic activity of cross-linking the side chains of lysine and glutamine residues via an amide bond in the MTG fusion of the present invention. Specifically, microbial transglutaminase functions as the cross-linking catalytic domain in the MTG fusion of the present invention.

[0025] As used herein, the term "antibody-binding domain" refers to a peptide domain in the MTG fusion of the present invention that has binding affinity to an antibody. In the MTG fusion of the present invention, specifically, an antibody-binding protein functions as the antibody-binding domain.

[0026] As used herein, "Microbial transglutaminase (often abbreviated as "MTG")" refers to transglutaminase (TGase) derived from Streptomyces mobaraensis, a type of actinomycete. Unlike TGases from other organisms, it requires the cofactor Ca for activity.2+ MTG catalyzes the acyl transfer reaction between the gamma-carboxyamide group in the side chain of glutamine residue (Q) and the amino group and primary amine in the side chain of lysine residue (K) in proteins. MTG is produced as an inactive microbial transglutaminase precursor in microorganisms such as Escherichia coli.

[0027] As used herein, the term "microbial transglutaminase precursor (often referred to as "ProMTG" herein)" refers to mature MTG that contains a propeptide region at the N-terminus. Wild-type ProMTG is an inactive MTG form.

[0028] As used herein, the "propeptide region" refers to the 46 amino acid residues located at the N-terminus of ProMTG (see Figure 2A). The propeptide region functions as an intramolecular chaperone, assisting in the folding of MTG, and is an essential domain for soluble expression in microorganisms. On the other hand, the propeptide region also functions as an inhibitor (quencher) that suppresses the activity of mature microbial transglutaminase.

[0029] As used herein, "wild-type microbial transglutaminase precursor (often referred to as "wild-type ProMTG" herein)" refers to ProMTG in a state in which the propeptide region suppresses the cross-linking activity of the microbial transglutaminase mature product.

[0030] As used herein, "mature microbial transglutaminase (or "mature microbial transglutaminase")" refers to active MTG, which is activated by removing the propeptide region from ProMTG with a protease. In this specification, when "MTG" is simply referred to, it includes both active and inactive MTG, unless otherwise specified.

[0031] As used herein, "active microbial transglutaminase precursor (active ProMTG)" refers to a mutant ProMTG that has been made active despite being a precursor by introducing a mutation into the propeptide region of wild-type ProMTG to create a mutant propeptide region.

[0032] As used herein, the term "mutant propeptide region" refers to a propeptide region in which a mutation has been introduced into an amino acid residue in the wild-type propeptide region present on the N-terminal side of wild-type ProMTG, and which has lost the quencher function that inhibits MTG activity.

[0033] As used herein, the term "antibody-binding protein" refers to a group of proteins that have the ability to bind to immunoglobulins.

[0034] The term "Fab region" refers to a region present in the heavy and light chains of an antibody, and composed of the variable region and C1 region (constant region 1) of each.

[0035] The term "Fc region" refers to a region present only in heavy chains, and is composed of CH2 and CH3 regions of the heavy chain.

[0036] As used herein, "amino acid identity" refers to the percentage (%) of matching amino acid residues in the total number of amino acid residues when two amino acid sequences are compared and aligned by inserting appropriate gaps into one or both sequences as needed to maximize the number of identical amino acid residues. Alignment of two amino acid sequences to calculate amino acid identity can be performed using known programs such as Blast, FASTA, and ClustalW.

[0037] As used herein, "base identity" refers to the percentage (%) of the number of matching bases in the total number of bases when two base sequences are compared and aligned by inserting appropriate gaps into one or both of them as necessary to maximize the number of matching bases.

[0038] As used herein, "plurality" refers to, for example, 2 to 20, 2 to 15, 2 to 10, 2 to 7, 2 to 5, 2 to 4, or 2 to 3. Additionally, "several" refers to 2 to 3.

[0039] As used herein, "(amino acid) substitution" refers to a substitution within a conservative amino acid group that has similar properties, such as charge, side chain, polarity, and aromaticity, among the 20 amino acids that constitute natural proteins. Examples include substitutions within the uncharged polar amino acid group with a low-polarity side chain (Gly, Asn, Gln, Ser, Thr, Cys, Tyr), the branched-chain amino acid group (Leu, Val, Ile), the neutral amino acid group (Gly, Ile, Val, Leu, Ala, Met, Pro), the neutral amino acid group with a hydrophilic side chain (Asn, Gln, Thr, Ser, Tyr, Cys), the acidic amino acid group (Asp, Glu), the basic amino acid group (Arg, Lys, His), and the aromatic amino acid group (Phe, Tyr, Trp). Amino acid substitutions within these groups are preferred because they are known to be less likely to cause changes in the properties of peptides.

[0040] As used herein, the term "linker" refers to a peptide chain that crosslinks the bridging catalytic domain and the antibody-binding domain in the MTG fusion of the present invention. In the MTG fusion containing a linker, the peptide chain of the bridging catalytic domain and the peptide chain of the antibody-binding domain are indirectly linked via the linker.

[0041] As used herein, the term "vector" refers to a nucleic acid molecule for transporting genes and the like, and is used in gene recombination techniques for gene recombination manipulation, intracellular introduction, replication, expression, and the like of foreign DNA.

[0042] As used herein, the term "transformant" refers to a host cell transformed by introducing a foreign gene into the cell, including a host cell into which a foreign gene has been introduced by infection (transfection) with various viruses and phages.

[0043] As used herein, the term "antibody modifying agent" refers to a cross-linking agent that modifies an antibody by cross-linking a substrate molecule to a specific amino acid residue of the antibody. The antibody modifying agent herein includes the MTG fusion protein as an active ingredient with cross-linking activity.

[0044] As used herein, the term "combined antibody modifying agent" refers to a composition containing two or more MTG fusions as active ingredients as antibody modifying agents.

[0045] As used herein, the term "substrate molecule" refers to a molecule that can serve as a substrate for MTG together with an antibody in a crosslinking reaction using an MTG fusion protein of the present invention. Examples of such molecules include nucleic acids, (poly)peptides, low-molecular-weight compounds, or combinations thereof. The substrate molecule contains an amino acid residue (lysine residue or glutamine residue) that serves as a reactive site in the crosslinking reaction. The substrate molecule may also contain an azide group, an alkynyl group, or a cycloalkynyl group.

[0046] As used herein, the term "peptide tag" refers to a peptide chain that provides a substrate molecule with an amino acid residue (lysine residue or glutamine residue) that serves as a reactive site in a crosslinking reaction. When a substrate molecule does not have an amino acid that serves as a reactive site, modification of the substrate molecule with a peptide tag is essential.

[0047] As used herein, the term "antibody-enzyme conjugate" refers to a conjugate of an MTG fusion as an enzyme and an antibody. This is one of the intermediates formed during the process of producing an enzyme-substrate conjugate in the method for producing an antibody-substrate conjugate described in the third aspect of the present invention. This conjugate is formed by binding to the target antibody to be modified via the antibody-binding domain contained in the MTG fusion of the present invention.

[0048] As used herein, the term "enzyme-antibody substrate conjugate" refers to a conjugate consisting of three molecules in which a substrate molecule is crosslinked to a specific amino acid residue in the antibody portion of the antibody-enzyme conjugate. In the antibody-substrate conjugate production method according to the third aspect of the present invention, the MTG fusion molecule that is no longer needed after the crosslinking reaction during the process of producing the antibody-substrate conjugate described below, which is the final product, is an intermediate that remains bound to the antibody-substrate conjugate.

[0049] As used herein, the term "antibody-substrate complex" refers to a complex in which an antibody is linked to a substrate molecule, and in this specification, corresponds to the final product produced by the method for producing an antibody-substrate complex according to the third aspect of the present invention.

[0050] As used herein, the term "antibody-drug conjugate (ADC)" refers to an antibody-substrate conjugate in which the substrate molecule is a drug, particularly a low molecular weight compound with cell-killing effect.

[0051] 1-3. Structure 1-3-1. Components of MTG fusion protein A schematic diagram of the MTG fusion protein of the present invention is shown in Figure 1. As shown in this figure, the MTG fusion protein (0100) of the present invention contains active ProMTG (0101) and an antibody-binding protein (0102) on the polypeptide chain as essential components, and also contains a linker (0103) as an optional component. Each component is explained below.

[0052] (1) Active proMTG (active microbial transglutaminase precursor) Active ProMTG (0101) is a mutant ProMTG that has cross-linking catalytic activity in the precursor state, and catalyzes the cross-linking reaction between target antibodies and substrate molecules as a cross-linking catalytic domain in MTG fusion proteins.

[0053] As mentioned above, wild-type ProMTG is in an inactive state, with its activity suppressed by the propeptide region at its N-terminus. However, when a mutation is introduced into the propeptide region of wild-type ProMTG to form the mutant propeptide region (0104), it changes from an inactive form to an active ProMTG.

[0054] The propeptide region consists of 46 amino acid residues located on the N-terminus of wild-type ProMTG. Wild-type ProMTG can consist of any of the following amino acid sequences: (a) the amino acid sequence shown in SEQ ID NO: 1; (b) the amino acid sequence shown in SEQ ID NO: 1 with one or more amino acid residues added, deleted, and / or substituted at positions other than 10, 12, 16, 25, and 27; or (c) an amino acid sequence having 90% or greater amino acid identity with the amino acid sequence shown in SEQ ID NO: 1. Thus, the propeptide region corresponds to the 46 amino acid residues from the methionine residue at position 1 to the proline residue at position 46 in the amino acid sequence shown in SEQ ID NO: 1. Meanwhile, the amino acid sequence from the aspartic acid residue at position 47 onward constitutes the amino acid sequence of mature MTG.

[0055] The introduction of such mutations as addition, deletion, or substitution in the amino acid sequence of the propeptide region or the like can be carried out using a commercially available kit for mutagenesis that utilizes site-directed mutagenesis. TM Site-Directed Mutagenesis System (Thermo Fisher Scientific), Prime STAR® Mutagenesis Basal kit (Takara Bio Inc.), Mutan TM -Super Express Km (Takara Bio Inc.), etc. The introduction of these mutations can be confirmed by various amino acid sequencing methods, and structural analysis methods such as X-ray and NMR.

[0056] Specific examples of mutations of amino acid residues in the mutant propeptide region include substitutions of the lysine residue at position 10, the tyrosine residues at positions 12 and 16, and / or the asparagine residues at positions 25 and 27 in the amino acid sequence of the propeptide region with other amino acid residues (in this specification, such amino acid substitutions, for example, substitutions of the lysine residue at position 10 and the tyrosine residue at position 12, are often represented as "K10 / Y12").

[0057] Other amino acid residues substituted for the lysine residue include any amino acid selected from the group consisting of arginine residue (R), aspartic acid residue (D), glutamic acid residue (E), asparagine residue (N), glutamine residue (Q), serine residue (S), threonine residue (T), glycine residue (G), alanine residue (A), leucine residue (L), isoleucine residue (I), valine residue (V), cysteine ​​residue (C), tryptophan residue (W), phenylalanine residue (F), methionine residue (M), proline residue (P), tyrosine residue (T), and histidine residue (H). Preferred are arginine residue, aspartic acid residue, or glutamic acid residue.

[0058] Other amino acid residues that can be substituted for the tyrosine residue include alanine, glutamine, or histidine residues.

[0059] Other amino acid residues that can be substituted for the asparagine residue include aspartic acid, glutamic acid, or serine residues.

[0060] As the mutation positions of the lysine residue, tyrosine residue, and asparagine residue in the propeptide region, for example, when the N-terminal aspartic acid residue is positioned at position 1 in the amino acid sequence shown in SEQ ID NO: 1, the lysine residue positioned at position 10 (often referred to herein as "K 10 "), tyrosine residues at positions 12 and 16 (often referred to herein as "Y 12 "," "Y 16 "), and asparagine residues at positions 25 and 27 (often referred to herein as "N 25 "," "N 27"). Examples of such residues include the lysine residue at position 10, the tyrosine residues at positions 12 and 16, and the asparagine residues at positions 25 and 27 in SEQ ID NO: 1 in the wild-type ProMTG described in (b) and (c) above. Here, "corresponding positions" refers to the positions of the amino acid residues in the amino acid sequence shown in (b) or (c) of SEQ ID NO: 1 when the amino acid sequence shown in SEQ ID NO: 1 and the amino acid sequence shown in (b) or (c) are aligned so as to maximize the number of identical amino acid residues. The specific mechanism by which substitution of the specific amino acid residues in the propeptide region of ProMTG with specific amino acid residues results in the activation of the precursor has not been elucidated. However, it is speculated that the hydrogen bonds that contribute to the structural stability of the propeptide region are disrupted by the substitution of the amino acid residues, or that electrostatic repulsion by the substituted amino acid residues results in the activation of the precursor.

[0061] Specific examples of mutant propeptide regions include propeptide regions having two substitutions (herein, such amino acid substitutions are often referred to as "K10R / Y12A" and "K10R / Y16A") in the amino acid sequence set forth in SEQ ID NO: 1: a substitution of the lysine residue at position 10 with an arginine residue (herein, such amino acid substitutions are often referred to as "K10R"), and a substitution of the tyrosine residue at position 12 or 16 with an alanine residue (herein, such amino acid substitutions are often referred to as "Y12A" and "Y16A", respectively) (herein, such mutant propeptide regions are often referred to as "Pro(K10R / Y12A)" and "Pro(K10R / Y16A)", respectively). ProMTG containing such mutant propeptide regions (referred to herein as "Pro(K10R / Y12A)MTG" and "Pro(K10R / Y16A)MTG") can be active ProMTG.

[0062] In addition, a propeptide region having two substitutions (K10R and a mutation in which the asparagine residue at position 25 or 27 is replaced with an aspartic acid residue) (such amino acid substitutions are often referred to herein as "K10R / N25D" or "K10R / N27D", respectively) can also be an active form of ProMTG.

[0063] Furthermore, in addition to K10R, for example, two or more substitutions selected from the group consisting of Y12A, Y16A, N25D, and N27D, specifically, K10R / Y12A / Y16A, K10R / Y12A / N25D, K10R / Y12A / N27D, K10R / Y16A / N25D, K10R / Y16A / N27D, K10R / Propeptide regions having N25D / N27D, and K10R / Y12A / Y16A / N25D, K10R / Y12A / Y16A / N27D, K10R / Y12A / N25D / N27D, K10R / Y16A / N25D / N27D, or K10R / Y12A / Y16A / N25D / N27D can also be active ProMTG.

[0064] In the MTG fusion protein of the present invention, the active ProMTG may be either the full-length or a portion of ProMTG, so long as it maintains catalytic cross-linking activity. The term "part of ProMTG" as used herein refers to a partial fragment of ProMTG in which one or more amino acid residues have been deleted from the full-length ProMTG, while still maintaining catalytic cross-linking activity. TG activity can be evaluated and measured, for example, by fluorescence resonance energy transfer (FRET) or other methods.

[0065] (2) Antibody-binding protein The antibody-binding protein (0102) functions as an antibody-binding domain in the MTG fusion. This function allows the MTG fusion of the present invention to bind to a target antibody, thereby enabling the active MTG, which is a cross-linking catalytic domain, to come into close proximity with the target antibody, thereby improving the cross-linking reaction.

[0066] The antibody-binding protein is not limited as long as it has the ability to bind to immunoglobulin. Immunoglobulins are known to be classified into IgG, IgM, IgA, IgE, and IgD classes, and the immunoglobulin of the present invention may be of any class. IgG is preferred.

[0067] Examples of antibody-binding proteins include, but are not limited to, protein G and protein A. Each of these will be explained in detail below.

[0068] (Protein G) "Protein G" (often referred to as "pG" herein) is a protein present in the cell wall of group G streptococci that has affinity for immunoglobulin G (IgG). pG consists of 12 domains, E, A1, B1, A2, B2, A3, S, C1, D1, C2, W, and M from the N-terminus. It has affinity for and can bind to all subclasses of IgG, from human to mouse. Therefore, the target IgG of pG contained in the MTG fusion of the present invention can be of any species. Mammalian IgG is preferred, and human IgG is more preferred. pG binds to the interface between the CH2 and CH3 constant domains of the IgG Fc region and to the CH1 constant domain of the Fab region. pG binds more strongly to the Fc region of human IgG than to the Fab region, but more strongly to the Fab region of mouse IgG. pG is a preferred protein as the antibody-binding protein in the MTG fusion of the present invention.

[0069] (Protein A) "Protein A" (often referred to as "pA" herein) is a protein present in the cell wall of Staphylococcus aureus. pA contains five homologous domains, domains E, D, A, B, and C from the N-terminus, and interacts strongly with the Fc region of IgG and weakly with the Fab region. It can bind to IgG from many species, from human to mouse IgG, but its binding strength differs depending on the IgG subclass. pA interacts with the interface between the CH2 and CH3 constant domains of the IgG Fc region, and binds to the IgG Fc region in almost the same region as pG.

[0070] (Wild-type and mutant-type antibody-binding proteins) The antibody-binding proteins contained in the MTG fusion proteins of the present invention may be wild-type or mutant-type, as long as they maintain antibody-binding ability.

[0071] A specific example of the amino acid sequence of wild-type pG is the amino acid sequence shown in SEQ ID NO: 3. Furthermore, an example of the amino acid sequence of mutant pG is an amino acid sequence in which one or more amino acid residues have been added, deleted, and / or substituted in the amino acid sequence shown in SEQ ID NO: 3, or an amino acid sequence having 90% or more amino acid identity with the amino acid sequence shown in SEQ ID NO: 3.

[0072] A specific amino acid sequence of wild-type pA is, for example, the amino acid sequence shown in SEQ ID NO: 5. Furthermore, an amino acid sequence of mutant pA is, for example, an amino acid sequence in which one or more amino acid residues have been added, deleted, and / or substituted in the amino acid sequence shown in SEQ ID NO: 5, or an amino acid sequence having 90% or more amino acid identity with the amino acid sequence shown in SEQ ID NO: 5.

[0073] Furthermore, when an antibody-binding protein contains multiple antibody-binding regions, it may be a mutant antibody-binding protein in which mutations have been introduced so that it binds only to a specific region of the antibody. For example, wild-type pG has a Fab-binding region and an Fc-binding region that recognize and bind to the Fab and Fc regions of IgG, respectively. However, as described below, an example of an Fc-binding pG is one in which a mutation has been introduced into the Fab-binding region to eliminate Fab-binding ability, thereby improving Fc-binding specificity using the remaining Fc antibody-binding region. When an antibody-binding protein contains multiple antibody-binding regions, there is a possibility that the antibody will aggregate upon reaction with the MTG fusion of the present invention. The mutant antibody-binding protein allows the MTG fusion to specifically bind to a specific region of the antibody, thereby making it possible to suppress such aggregation.

[0074] Examples of mutant antibody-binding proteins having such a structure include Fab-binding protein G, Fc-binding protein G, and protein Z (often referred to as "pZ" herein).

[0075] "Fab-binding protein G" (often referred to herein as "pG(Fab)") is a mutant pG in which mutations have been introduced into the Fc-binding region of pG, resulting in loss of Fc-binding ability and enhanced binding specificity to the Fab region. The Fab-binding region of pG may, for example, consist of the amino acid sequence shown in SEQ ID NO: 7. As used herein, pG(Fab) primarily refers to a mutant pG(Fab) (often referred to herein as "pG(Fab)-ΔKQ") that contains amino acid substitutions at all lysine and glutamine residues in the Fab-binding region and that can suppress pG self-labeling and antibody aggregation when incorporated into the MTG fusion protein of the present invention, but is not limited thereto. A more specific example of pG(Fab)-ΔKQ is pG(Fab)-ΔKQ shown in SEQ ID NO: 8, in which all lysine and glutamine residues in the amino acid sequence shown in SEQ ID NO: 7 have been substituted with other amino acid residues (e.g., arginine and asparagine residues, respectively).

[0076] "Fc-binding protein G" (often referred to herein as "pG(Fc)") is a mutant pG in which mutations have been introduced into the Fab-binding region of pG, resulting in loss of binding ability to Fab fragments and thereby enhanced binding specificity to the Fc region. The Fc-binding region of pG consists, for example, of the amino acid sequence shown in SEQ ID NO: 9. As used herein, pG(Fc) includes mutant pG(Fc) that contains amino acid substitutions in all or part of the lysine and glutamine residues in the Fc-binding region and that can suppress autolabeling when incorporated into the MTG fusion of the present invention. More specifically, for example, there is pG(Fc) shown in SEQ ID NO: 10, in which five lysine residues in the amino acid sequence shown in SEQ ID NO: 9 have been substituted with other amino acid residues (e.g., arginine residues) (in the present specification, such pG(Fc) is often referred to as "pG(Fc)-ΔKx5". Note that a mutant pG containing amino acid substitutions at all lysine and glutamine residues in the Fc binding region is often referred to as "pG(Fc)-ΔKQ").

[0077] "Protein Z" (often referred to herein as "Fc-binding protein A" or "pZ") is a protein in which two mutations have been made to the B domain of pA: A1V for cloning and G29A for providing resistance to hydroxylamine treatment. As a result, pZ loses its ability to bind to the Fab region of IgG and binds only to the Fc region. Examples of mutant pZ include the Ca2+-binding protein A used in this example. 2+ pZ shown in SEQ ID NO: 33 to which binding ability has been imparted Ca2+ , pZ Ca2+ pZ shown in SEQ ID NO: 34 in which all lysine residues in Ca2+ (ΔK), and further includes pZ(ΔK, Alkaline stabilized) shown in SEQ ID NO: 35, which is an alkali-tolerant mutant of pZ in which all lysine residues in the pZ(Alkaline stabilized) sequence have been replaced with arginine residues.

[0078] (3) Linker: A "linker" (0103) refers to a peptide chain that mediates the bond between activated ProMTG and the antibody-binding protein in the MTG fusion of the present invention. The linker alleviates steric hindrance caused by the direct fusion of activated ProMTG and the antibody-binding protein, and may have the function of improving the cross-linking reaction between the target antibody and the substrate molecule by increasing the flexibility of activated ProMTG, which has cross-linking catalytic activity, when the MTG fusion binds to the target antibody via the antibody-binding protein.

[0079] The length and amino acid sequence of the linker are not particularly limited. For example, it may be composed of 1 to 50, 4 to 40, 6 to 30, or 8 to 20 amino acid residues. The type of linker is also not particularly limited. Various linkers for linking two peptide fragments are known in the art, and any of them can be used. Specific examples include a peptide linker containing GGGGS (SEQ ID NO: 32) as one unit (often referred to herein as "G4S"), a linker in which 2 to 5 such units are linked (for example, a linker in which three units as shown in SEQ ID NO: 11 are linked is often referred to as "(G4S)3"), the thrombin linker (GGGSLVPRGSGGGS) shown in SEQ ID NO: 12, the polyproline linker (PPPP) shown in SEQ ID NO: 37, the IgA linker (AAASPSTPPTPSPSTPPA) shown in SEQ ID NO: 38, and the HAtag linker (YPYDVPDYA) shown in SEQ ID NO: 39.

[0080] As will be described in the Examples below, linkers containing one or more negatively charged amino acid residues (D: aspartic acid or E: glutamic acid), such as the HAtag linker, are particularly preferred because they can enhance the antibody modification rate. Such linkers may also be mutant linkers in which some of the amino acid residues in known linkers have been substituted with negatively charged amino acid residues. Examples include the mutant HAtag linkers shown in SEQ ID NOs: 40 to 48 in which one or more of the two amino acid residues from the N-terminus of the HAtag linker shown in SEQ ID NO: 39 (the tyrosine residue at position 1 and the proline residue at position 2) have been substituted with aspartic acid or glutamic acid.

[0081] 1-3-2. Structure of MTG Fusion Protein The MTG fusion protein of the present invention may have a structure in which active ProMTG and the antibody-binding protein are directly linked by a peptide bond, or may have a structure in which the two proteins are indirectly linked via a linker.

[0082] In either the direct or indirect linkage, the order in which activated ProMTG and the antibody-binding protein are linked is not important. For example, activated ProMTG may be located at the N-terminus of the MTG fusion, and the antibody-binding protein at the C-terminus. Conversely, the antibody-binding protein may be located at the N-terminus of the MTG fusion, and activated ProMTG at the C-terminus. Depending on this order of placement, the orientation of activated ProMTG toward the antibody in the MTG fusion of the present invention may change, and as a result, the modification position on the IgG (position of the cross-linking amino acid residue) may also change.

[0083] For example, when the antibody-binding protein is pG, the target amino acid residues on IgG are different between an MTG fusion in which the order of NH2-active ProMTG-pG-COOH is arranged (often referred to herein as "active ProMTG-pG") and an MTG fusion in which the order of active ProMTG and pG is reversed and the order is NH2-pG-active ProMTG-COOH (often referred to herein as "pG-active ProMTG").

[0084] Specifically, for example, active ProMTG-pG (Fab-ΔKQ) has a lysine residue (K) at position 65 in CDR2 (Complementarity Determining Region) in the variable region of the IgG heavy chain Fab region. 65 However, in pG(Fab-ΔKQ)-active ProMTG, the lysine residue at position 225 (K) in the heavy chain hinge region is selectively modified. 225 ) as the target amino acid residue. Based on this selective modification, antibodies can be modified at specific positions (e.g., K 65 or K 225 ) single point marking is possible.65 and K. 225 are modification positions in the native IgG sequence that are modified by the MTG fusion compound, and the modification positions may change when one or more bases are added and / or deleted in IgG or when antibodies other than IgG are modified. In this specification, even in such cases, the lysine residues corresponding to the two modification positions are referred to as K and K, respectively. 65 and K. 225 It will be written as:

[0085] The MTG fusion protein of the present invention is not limited and may be a peptide derived from a natural product or may be one obtained by artificial chemical synthesis.

[0086] Proteins derived from natural products may be obtained directly from natural products by known recovery and purification methods, or may be obtained by inserting a gene encoding the protein into various expression vectors or the like using known gene recombination techniques, introducing the vector into cells, allowing the protein to be expressed, and then recovering and purifying the protein by known recovery and purification methods. Alternatively, the protein may be obtained from commercially available kits, such as the PROTEIOS Reagent Kit. TM The protein may be produced in a cell-free protein synthesis system using a system such as TnT (registered trademark) System (Promega) or the like, and then recovered and purified by known methods, without any particular limitation.

[0087] Chemically synthesized proteins can be obtained using known protein synthesis methods. Examples of synthesis methods include the azide method, acid chloride method, acid anhydride method, mixed acid anhydride method, DCC method, active ester method, carboimidazole method, and oxidation-reduction method. Both solid-phase synthesis and liquid-phase synthesis can be used for the synthesis. A commercially available protein synthesizer may also be used. After the synthesis reaction, the protein can be purified by a combination of known purification methods such as chromatography.

[0088] Furthermore, the MTG fusion protein of the present invention may contain its derivatives, which include all derivatives that can be prepared from the protein, such as those in which some of the constituent amino acids have been substituted with unnatural amino acids or those in which some of the constituent amino acids (mainly their side chains) have been chemically modified.

[0089] The MTG fusion of the present invention may also contain salts of the protein and / or derivative. Such salts are preferably physiologically acceptable acid addition salts or base salts. Examples of acid addition salts include salts with inorganic acids such as hydrochloric acid, phosphoric acid, hydrobromic acid, and sulfuric acid, and salts with organic acids such as acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, and benzenesulfonic acid. Examples of base salts include salts with inorganic bases such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, and magnesium hydroxide, and salts with organic bases such as caffeine, piperidine, trimethylamine, and pyridine. Such salts can be prepared using an appropriate acid such as hydrochloric acid or an appropriate base such as sodium hydroxide. For example, they can be prepared by treating the protein or derivative in water or in an inert, water-miscible organic solvent such as methanol, ethanol, or dioxane using standard protocols.

[0090] 1-3-3. Nucleic Acid Encoding MTG Fusion The nucleic acid encoding the MTG fusion of the present invention (often referred to herein as a "transglutaminase fusion gene (TG fusion gene)") is a recombinant nucleic acid molecule constructed by genetic engineering. This TG fusion gene is essentially composed of natural nucleic acids. "Natural nucleic acids" refer to naturally occurring biopolymers whose structural units are nucleotides linked by phosphodiester bonds. Typically, this refers to RNA linked to ribonucleotides containing any of the bases adenine, guanine, cytosine, and uracil, and / or DNA linked to deoxyribonucleotides containing any of the bases adenine, guanine, cytosine, and thymine. The TG fusion gene may be composed of DNA, RNA, or a combination thereof.

[0091] The specific nucleotide sequence of the TG fusion gene of the present invention is not limited as long as it encodes the MTG fusion described in aspect 1. MTG fusions include active ProMTG and antibody-binding proteins, and examples of nucleotide sequences encoding wild-type ProMTG include: (a) the nucleotide sequence shown in SEQ ID NO: 2, which encodes the amino acid sequence shown in SEQ ID NO: 1; (b) a nucleotide sequence in which one or more nucleotides have been added, deleted, and / or substituted at positions other than positions 27-29 and 33-35 of the nucleotide sequence shown in SEQ ID NO: 2; (c) a nucleotide sequence that shares 95% or more nucleotide identity with the nucleotide sequence shown in SEQ ID NO: 2; and (d) a nucleotide sequence that hybridizes under highly stringent conditions with a nucleic acid fragment consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 2. Examples of nucleotide sequences encoding wild-type pG include (e) the nucleotide sequence shown in SEQ ID NO: 4, which encodes the amino acid sequence shown in SEQ ID NO: 3, (f) the nucleotide sequence shown in SEQ ID NO: 4 in which one or more nucleotides have been added, deleted, and / or substituted, (g) a nucleotide sequence having 95% or more nucleotide identity with the nucleotide sequence shown in SEQ ID NO: 4, and (h) a nucleotide sequence that hybridizes under highly stringent conditions with a nucleic acid fragment consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 4. Examples of nucleotide sequences encoding wild-type pA include (i) the nucleotide sequence shown in SEQ ID NO: 6, which encodes the amino acid sequence shown in SEQ ID NO: 5, (j) the nucleotide sequence shown in SEQ ID NO: 6 in which one or more nucleotides have been added, deleted, and / or substituted, (k) a nucleotide sequence having 95% or more nucleotide identity with the nucleotide sequence shown in SEQ ID NO: 6, and (l) a nucleotide sequence that hybridizes under highly stringent conditions with a nucleic acid fragment consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 6. Here, "highly stringent conditions" refers to high temperature and low salt conditions under which nonspecific hybrids are not formed. For example, post-hybridization washing conditions are 60°C to 68°C and 1×SSC or less, preferably 65°C to 70°C and 0.1×SSC or less. Here, 1×SSC may contain 150 mM sodium chloride and 15 mM sodium citrate.

[0092] The TG fusion gene of the present invention may be labeled with a nucleic acid labeling substance at the phosphate group, sugar, and / or base, as needed. Any substance known in the art can be used as the nucleic acid labeling substance. For example, a radioisotope (e.g., 32 P, 3 H, 14 Examples of suitable fluorescent dyes include FITC, Texas, cy3, cy5, cy7, FAM, HEX, VIC, JOE, Rox, TET, Bodipy493, NBD, and TAMRA, and luminescent substances such as acridinium ester.

[0093] The TG fusion gene of the present invention can be prepared by cloning techniques. For example, but not limited to, a DNA fragment containing the base sequence shown in SEQ ID NO: 2 encoding wild-type ProMTG and a DNA fragment containing the base sequence shown in SEQ ID NO: 4 encoding wild-type pG can be ligated into a cloning vector, and then a mutation can be introduced at a predetermined site using a site-directed mutagenesis method such as the Kunkel method or the gapped duplex method. The introduction of a base mutation can be performed using a commercially available site-directed mutagenesis kit. Examples of such kits include the commercially available QuickChange Site-Directed Mutagenesis Kit (Agilent Technology) and GeneTailor TM Site-Directed Mutagenesis System (Thermo Fisher Scientific), Mutan TM-Super Express Km (Takara Bio Inc.). Alternatively, the vector can be prepared by a known nucleic acid amplification method such as PCR using primers designed to introduce the desired missense mutation, with DNA comprising the nucleotide sequence shown in SEQ ID NO: 2 encoding wild-type ProMTG and DNA comprising the nucleotide sequence shown in SEQ ID NO: 4 encoding wild-type pG as templates. These cloning techniques are well known in the art, and reference may be made to the techniques described in, for example, Green & Sambrook, Molecular Cloning, A Laboratory Manual 4th ed., Cold Spring Harbor Laboratory Press (2012), Current Protocols in Molecular Biology, Wiley online library (2023), etc.

[0094] (1) Vector The TG fusion gene of the present invention may be contained in a vector. A vector is a nucleic acid molecule for transporting genes, etc., and is used in genetic engineering for genetic recombination manipulation, intracellular introduction, replication, expression, etc. of foreign DNA. Known types of vectors include cloning vectors, expression vectors, and recombinant expression vectors, and the vector of the present invention may be any of these. A "cloning vector" refers to a vector primarily used for gene cloning. This primarily applies to vectors that can produce a large number of copies in microbial hosts such as E. coli and yeast. An "expression vector" refers to a vector that contains a nucleic acid molecule (e.g., a gene or gene fragment) encoding a protein, etc., in an expressible state and can control the expression of the nucleic acid molecule. As used herein, "expressible state" refers to a state in which the gene, etc. is placed under the control of a promoter, and expression of the gene, etc. can be induced by promoter activation. Furthermore, a "recombinant expression vector" refers to a vector that incorporates the characteristics of both a cloning vector and an expression vector. The vector of the present invention may be any vector that contains the TG fusion gene, depending on the circumstances.

[0095] The type of vector is not limited as long as it can contain the TG fusion gene, and a vector suitable for the host to be used can be appropriately selected and used. Specific examples of vector configurations include plasmid DNA, bacteriophage, retrotransposon, insect virus vectors such as baculovirus, bacmid, retrovirus vector, and artificial chromosomes (HAC, MAC, YAC, etc.).

[0096] (2) Transformant The vector containing the TG fusion gene of the present invention can be introduced into a host cell to produce a transformant. If the vector is an expression vector, the transformant can be cultured and subjected to an appropriate expression induction treatment to express the MTG fusion gene of the present invention.

[0097] The host is not limited and can be selected appropriately depending on the application, etc. For example, known hosts such as bacteria, yeast, insects, animal cells such as human and mouse cells, insect cells, and plant cells can be used. When a bacterium is used as the host, for example, Escherichia coli, Bacillus subtilis, etc. are used. When a yeast is used as the host, for example, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris, etc. are used. When an insect is used as the host, for example, Bombyx mori, Bombyx mandarina, Antheraea yamamai, Samia cynthia, etc. are used. When animal cells are used as hosts, established cell lines such as HeLa cells, HEK293 cells, NIH3T3 cells, CHO cells, human fibroblasts, FL cells, COS-7 cells, Vero cells, L cells, and GH3 cells are used. Furthermore, when insect cells are used as hosts, Sf9 cells, Sf21 cells, etc. can also be used. When plant cells are used as hosts, BY-2 cells, etc. are used.

[0098] The transformation method for introducing the vector into a host cell is not particularly limited, and any method known in the art can be appropriately selected taking into consideration the combination of the host and expression vector. For example, electroporation, lipofection, heat shock, PEG, calcium phosphate, DEAE-dextran, protoplast, particle gun, Agrobacterium, and viral infection can be used.

[0099] 1-4. Method for Producing an MTG Fusion Protein The method for producing an MTG fusion protein of the present invention comprises a mutation introduction step, a linking step, and an expression step. Of these steps, the order of the mutation introduction step and the linking step is not important. The mutation introduction step may be performed first, or the linking step may be performed first. Each step will be explained below.

[0100] The "mutation introduction step" is a step of introducing mutations into codons encoding at least one tyrosine residue and a lysine residue, at least one asparagine residue and a lysine residue, or at least one asparagine residue, at least one tyrosine residue and a lysine residue in the propeptide region of a nucleic acid fragment (DNA fragment) containing the base sequence shown in SEQ ID NO: 2 that encodes wild-type ProMTG, substituting them with other amino acid residues. As long as the mutation allows for the substitution of the target amino acid residue with another amino acid residue, it may be a substitution of one base in a triplet codon, or it may be a substitution of all three bases. The method for introducing a mutation into a specific base in a nucleic acid fragment encoding wild-type ProMTG may utilize the site-directed mutagenesis method described above.

[0101] The "ligation step" is a step of ligating a nucleic acid fragment encoding ProMTG with a nucleic acid fragment encoding an antibody-binding protein to prepare a transglutaminase fusion gene encoding a microbial transglutaminase fusion protein. Both nucleic acid fragments may be linked via a linker consisting of a peptide chain. The nucleic acid fragments can be ligated by known cloning techniques based on molecular genetics. The cloning technique may be performed in accordance with the method described above.

[0102] The "expression step" is a step in which the TG fusion gene prepared in the ligation step is expressed in a host cell. To express the TG fusion gene in a host cell, for example, the TG fusion gene may be incorporated into an expression vector. The expression vector is then introduced into the host cell, the transformant is cultured, and an expression induction treatment is performed as necessary, thereby producing the desired MTG fusion product in the host cell. The incorporation of the TG fusion gene into the expression vector, the introduction of the resulting expression vector into the host cell, the induction of expression of the TG fusion gene in the transformant, and the production of the desired MTG fusion product can be carried out in accordance with the descriptions in "(1) Vector" and "(2) Transformant" above.

[0103] 2. Antibody Modifying Agents 2-1. Overview A second aspect of the present invention is an antibody modifying agent. The antibody modifying agent of the present invention contains the MTG fusion described in the first aspect as an active ingredient and is capable of modifying an antibody with a substrate molecule in a crosslinking reaction between the antibody and the substrate molecule. The antibody modifying agent of the present invention enables single-point crosslinking of a substrate molecule to a specific lysine residue on an antibody. Furthermore, by combining the antibody modifying agent with another antibody modifying agent to form a combined antibody modifying agent, it is possible to specifically modify the same or different substrate molecules at specific lysine and arginine residues on an antibody.

[0104] 2-2. Configuration The antibody modifying agent of the present invention may be a drug composed of the MTG fusion protein alone, or may be a composition containing a carrier.

[0105] The antibody modifying agent of the present invention comprises, as an active ingredient, an MTG fusion having any of the configurations described in the first aspect. The MTG fusion described in the first aspect has the activity of catalyzing a cross-linking reaction between a specific lysine residue in an antibody and a glutamine residue in a substrate molecule.

[0106] As described in the first aspect, the target position of the specific lysine residue varies depending on the structure of the MTG fusion product included. For example, in an MTG fusion product containing active ProMTG at the N-terminus and wild-type or mutant pG at the C-terminus (e.g., Pro(K10R / Y12A)MTG-pG(Fab-ΔKQ)), the target position is the lysine residue at position 65 of the IgG heavy chain (K 65 ) and this K65 Furthermore, an MTG fusion molecule containing wild-type or mutant pG at the N-terminus and active ProMTG at the C-terminus (e.g., pG(Fab-ΔKQ)-Pro(K10R / Y12A)MTG) can selectively and specifically modify the substrate molecule by the lysine residue at position 225 of the IgG heavy chain (K 225 ) and this K 225 Thus, by containing one of the MTG fusions described in the first embodiment as an active ingredient, the antibody modifying agent of the present invention can modify a specific lysine residue on an antibody at a single point.

[0107] On the other hand, the antibody modifying agent of the present invention may be a combination antibody modifying agent containing a combination of two or more MTG fusions as active ingredients. A specific example of a combination antibody modifying agent may be an antibody modifying agent containing the aforementioned Pro(K10R / Y12A)MTG-pG(Fab-ΔKQ) and pG(Fab-ΔKQ)-Pro(K10R / Y12A)MTG. In this case, the K in the antibody (IgG) 65 and K. 225 By cross-linking these two lysine residues with glutamine residues contained in the substrate molecule, the substrate molecule can be selectively modified with the two lysine residues. The MTG fusion antibody modifying agent combination of the present invention makes it possible to selectively modify different specific lysine residues on an antibody with the same or different substrate molecules containing glutamine residues.

[0108] 2-2-2. Carrier In addition to the active ingredient, the antibody modifying agent of the present invention can contain a pharmaceutically acceptable carrier, if necessary. "Pharmaceutically acceptable carrier" refers to an additive commonly used in the pharmaceutical formulation field. Examples include solvents and / or excipients.

[0109] The solvent may be, for example, water or other pharmaceutically acceptable aqueous solutions, or pharmaceutically acceptable organic solvents. Examples of aqueous solutions include physiological saline, isotonic solutions containing glucose or other adjuvants, and buffers that promote the enzymatic reaction of MTG. Examples of adjuvants include, but are not limited to, D-sorbitol, D-mannose, D-mannitol, sodium chloride, low-concentration nonionic surfactants, and polyoxyethylene sorbitan fatty acid esters.

[0110] The excipient may include, for example, a solubilizer, a suspending agent, a diluent, a dispersing agent, a surfactant, a stabilizer, an adsorbent, a preservative, an antioxidant, and the like, as appropriate.

[0111] The carrier is used to maintain the catalytic activity of the MTG fusion compound, which is the active ingredient, and to facilitate the cross-linking reaction between the antibody and the substrate molecule, and may be used appropriately as needed.

[0112] 3. Method for Producing Antibody-Substrate Conjugates 3-1. Overview A third aspect of the present invention is a method for producing an antibody-substrate conjugate. In the production method of the present invention, an antibody-substrate conjugate is produced by cross-linking a substrate molecule to a specific amino acid residue in an antibody using the antibody modifying agent or antibody modifying agent combination described in the second aspect. The production method of the present invention makes it possible to simply produce an antibody-substrate conjugate in which an antibody is site-specifically and quantitatively modified with a substrate molecule.

[0113] The method for producing an antibody-substrate complex of the present invention includes, as essential steps, an antibody binding step, a cross-linking step, and an enzymatic separation step, and also includes, as selection steps, a substrate molecule modification step and a purification step. Each step will be described in detail below.

[0114] (1) Antibody binding step The "antibody binding step" is a step of mixing an antibody with any of the antibody modifying agents described in the second aspect, and binding the MTG fusion molecule contained in the antibody modifying agent to the antibody to prepare an antibody-enzyme complex.

[0115] The antibody used in this step is the antibody to be modified by the substrate molecule. There are no limitations on the type of antibody, as long as it can specifically recognize and bind to a specific target substance such as cancer cells. IgG is preferred, but other immunoglobulins such as IgA, IgM, IgE, and IgD may also be used.

[0116] The antibody modifying agent used in this step is appropriately selected depending on the modification site of the antibody. For example, when pinpointing a specific lysine residue in an antibody, an antibody modifying agent containing the MTG fusion molecule described in the first embodiment as an active ingredient may be used.

[0117] Specifically, for example, the heavy chain K of IgG 65 When modifying a nucleic acid, a nucleic acid modifying agent containing an MTG fusion molecule in which active ProMTG is located at the N-terminus, such as active ProMTG-pG, is used. Specific examples of such MTG fusion molecules include Pro(K10R / Y12A)MTG-pG, Pro(K10R / Y12A)MTG-pG(Fab-ΔKQ), and Pro(K10R / Y12A)MTG-pG(Fc-ΔKx5).

[0118] In addition, the heavy chain K of IgG 225 When modifying a nucleic acid, a nucleic acid modifying agent containing an MTG fusion in which active ProMTG is located at the C-terminus, such as pG-active ProMTG, is used. Specific examples of such MTG fusions include pG-Pro(K10R / Y12A)MTG, pG(Fab-ΔKQ)-Pro(K10R / Y12A)MTG, and pG(Fc-ΔKx5)-Pro(K10R / Y12A)MTG.

[0119] Therefore, the type of antibody modifying agent used in this step can be determined appropriately depending on the modification position and number of modifications on the antibody, and is not particularly limited. For example, when specifically modifying only one site on an antibody heavy chain, one type of antibody modifying agent can be used. Even in this case, since IgG is a bivalent antibody, each amino acid residue in the two heavy chains is modified, resulting in modification of two amino acid residues at the same position per IgG molecule. On the other hand, when selectively modifying amino acid residues at multiple sites on an antibody heavy chain, a combination antibody modifying agent containing multiple types of MTG fusions with different target amino acid residue positions can be used.

[0120] The method for mixing the antibody and antibody modifying agent is not particularly limited as long as it allows the two to come into contact and form an antibody-enzyme complex, but mixing is generally carried out in a reaction solution. The composition of the reaction solution is not particularly limited as long as it maintains the activity of active MTG, the cross-linking catalytic domain of the MTG fusion. Typically, mixing the antibody and antibody modifying agent in a buffer such as PBS (pH 7.4) is sufficient. The reaction conditions are also not particularly limited as long as they allow the MTG fusion to bind to the antibody and form an antibody-enzyme complex. For example, the antibody and antibody modifying agent may be mixed in a buffer and then allowed to stand for 5 minutes to 1 hour, 10 minutes to 40 minutes, or 20 minutes to 30 minutes at 4 to 40°C, 10 to 39°C, 15 to 39°C, 18 to 38°C, 20 to 38°C, 23 to 38°C, 25 to 37°C, 27 to 37°C, or 30 to 36°C.

[0121] (2) Substrate Molecule Modification Step The "substrate molecule modification step" is a step of pre-modifying a substrate molecule prior to the cross-linking step described below in order to install a chemically reactive group on the substrate molecule that will serve as a reactive site in the cross-linking reaction of the MTG fusion. This step is a selection step, and if the substrate molecule already contains a reactive site, selection is not necessarily required. Furthermore, since this step can be performed independently of the antibody binding step, the order of the steps is not important.

[0122] The substrate molecule used in this step is a substrate molecule that is crosslinked to the antibody by the catalytic activity of MTG during the production of an antibody-substrate complex. The type of substrate is not particularly limited. It may be appropriately selected from nucleic acids, (poly)peptides, sugar chains, lipids, low-molecular-weight compounds, or combinations thereof, depending on the purpose of the antibody-substrate complex to be produced. For example, if the purpose is the production of an ADC, the substrate molecule may be an anticancer drug. The type of anticancer drug is not limited, and examples thereof include paclitaxel, doxorubicin, daunorubicin, cyclophosphamide, methotrexate, 5-fluorouracil, thiotepa, busulfan, improsulfan, piposulfan, benzodopa, carboquone, meturedopa, uredopa, altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, trimethylolomelamine, bullatacin, bullatacinone, camptothecin, bryostatin, callystatin, cryptophycin 1, cryptophycin 8, dolastatin, duocarmycin, eleutherobin, pancratistatin, and sarcodictin. dictyin), spongistatin, chlorambucil, chlornaphazine, colofosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine, calicheamicin, dynemicin, clodronate, esperamicin, aclacinomycin, actinomycin, ausramycin, azaserine, bleomycin,Cactinomycin, carabicin, carminomycin, carzinophilin, chromomycin, dactinomycin, detorbicin, 6-diazo-5-oxo-L-norleucine, adriamycin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin C, mycophenolic acid acid), nogalamycin, olivomycin, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, pteropterin, trimetrexate, fludarabine Fludarabine, 6-mercaptopurine, thiamiprine, thioguanine, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, androgens, calusterone, dromostanolone propionate, epithiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, florinic acid acid), aceglatone, aldophosphamide glycoside, aminolevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene, edatraxate, defofamine, demecolcine, diaziquone, elfornithine,Elliptinium acetate, epothilone, etoglucid, lentinan, lonidamine, maytansine, ansamitocin, mitoguazone, mitoxantrone, mopidanmol, nitraerine, pentostatin, phenamet, pirarubicin, losoxantrone, podophyllinic acid, 2-ethylhydrazide, procarbazine, razoxane, rhizoxin, sizofiran, spirogermanium, tenuazonic acid acid), triaziquone, roridine A, anguidine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, doxetaxel, chlorambucil, gemcitabine, 6-thioguanine, mercaptopurine, cisplatin, oxaliplatin, carboplatin, vinbrain benzodiazepine (PBD) dimer, ravtansine, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), mertansine (DM1), tesirine, methadone ...Examples include trastuzumab.

[0123] The substrate molecule must contain a glutamine residue as a reactive site for the crosslinking reaction. Therefore, when the substrate molecule is not a (poly)peptide containing a glutamine residue, the purpose of this step is to modify the substrate molecule with a glutamine residue or a peptide tag containing such a residue.

[0124] The length of the amino acid sequence of the peptide tag is not particularly limited, as long as the peptide can serve as a reactive substrate. For example, the length may be 2 to 40 amino acids, 3 to 38 amino acids, 4 to 35 amino acids, 5 to 33 amino acids, 6 to 30 amino acids, 7 to 28 amino acids, 8 to 26 amino acids, 9 to 24 amino acids, 10 to 22 amino acids, or 12 to 20 amino acids. The specific amino acid sequence of the peptide tag is also not particularly limited, as long as it contains an amino acid residue (glutamine residue) that serves as a reactive site for MTG and can serve as a reactive substrate. A specific example includes, but is not limited to, a peptide tag having an amino acid sequence containing YPLQMRG (SEQ ID NO: 13), which contains a glutamine residue. The peptide tag may also have an azide group, an alkynyl group, or a cycloalkynyl group added. Examples of cycloalkynyl groups include click reaction elements.

[0125] As used herein, the term "click reaction element" refers to a reaction substrate that can undergo a click reaction with an azide group without the need for a copper catalyst. Examples include OCT (cyclooctyne), MFCO (monofluorinated cyclooctyne), DFCO (difluorinated cyclooctyne), DBCO (dibenzocyclooctyne), BIARC (biarylazacycloocthionone), BC (bicyclononyne), and DACN (diazacyclononyne).

[0126] The method for modifying the substrate molecule with a peptide tag is not particularly limited and may be based on a method known in the art depending on the type of substrate molecule.

[0127] When the substrate molecule is a low molecular weight compound such as TAMRA, if the peptide tag contains a glutamine residue, it can be bound to the N-terminal amino group of the peptide containing the glutamine residue via an amide group. Alternatively, if the peptide tag contains a lysine residue, the lysine can be blocked with a protecting group during solid-phase synthesis, the dye can be modified first using the above method, and the protecting group can be removed at the end. Furthermore, when the substrate molecule is a nucleic acid, the carboxylic acid of the peptide tag can be bound to a primary amine-modified nucleic acid via an amide bond. Furthermore, when an alkynyl group or cycloalkynyl group is added to the peptide tag, the peptide tag and the substrate molecule can also be bound by a click reaction with a substrate molecule to which an azide group has been added. Alternatively, when an azide group is added to the peptide tag, it can be similarly bound by a click reaction with a substrate molecule to which an alkynyl group or cycloalkynyl group has been added.

[0128] If the substrate molecule is a (poly)peptide, a lysine or glutamine residue may be added to a position (e.g., the N-terminus or C-terminus) that does not inhibit the activity of the (poly)peptide. Modifications may also be performed by contract synthesis at a life science manufacturer.

[0129] (3) Crosslinking Step The "crosslinking step" is a step of preparing an enzyme-antibody substrate conjugate by mixing the antibody-enzyme conjugate and a substrate molecule and crosslinking the substrate molecule to a specific amino acid residue in the antibody site of the antibody-enzyme conjugate using the TMG activity in the antibody-enzyme conjugate. In principle, this step is performed after the antibody binding step, but it can also be performed simultaneously with the antibody binding step. In this case, the substrate molecule modification step is performed prior to this step, and therefore the antibody binding step is also performed after the substrate molecule modification step.

[0130] The substrate molecule used in this step may be appropriately selected based on the antibody-enzyme complex obtained after the antibody-binding step. In the antibody-enzyme complex, the type of MTG fusion bound to the antibody determines whether lysine and / or glutamine residues on the antibody are modified, and further, if a lysine residue is modified, the position of the lysine residue to be modified. MTG catalyzes an acyl transfer reaction between glutamine and lysine residues, cross-linking both amino acid residues. Therefore, if the antibody modification position is a lysine residue, a substrate molecule containing a glutamine residue is used, and if it is a glutamine residue, a substrate molecule containing a lysine residue is used. The desired position to be cross-linked with the substrate molecule may be predetermined to determine which position on the antibody to modify.

[0131] Specifically, for example, the heavy chain K of IgG 65 or K 225 When modifying IgG heavy chain K by using a substrate molecule containing the peptide tag shown in SEQ ID NO: 13, the catalytic activity of MTG can be 65 or K 225 and the glutamine residue at position 4 (Q4) of the peptide tag shown in SEQ ID NO: 13.

[0132] In this step, even after the cross-linking reaction between the antibody and the substrate molecule is completed, the MTG fusion molecule remains bound to the antibody via the antibody-binding domain, forming an enzyme-antibody-substrate complex in which the three molecules are associated via the antibody.

[0133] (4) Enzyme Separation Step The "enzyme separation step" is a step in which the MTG fusion having enzymatic activity is separated from the enzyme-antibody substrate complex obtained after the crosslinking step to prepare the desired antibody-substrate complex. As described above, the antibody-substrate complex, which is the final product of the present invention, is produced after the crosslinking step. However, the MTG fusion used in the crosslinking reaction between the antibody and the substrate molecule remains bound to the antibody site of the antibody-substrate complex. The MTG fusion after the crosslinking step is no longer needed for the complex. Therefore, the purpose of this step is to separate and remove the MTG fusion from the enzyme-antibody substrate complex.

[0134] The method for separating the MTG fusion protein from the enzyme-antibody substrate complex is not limited. For example, the antibody and pG may be separated by contacting the antibody with a low- or high-pH solution that induces a reversible conformational change in the antibody. Specific examples include exchanging the reaction solution used in the crosslinking step for a glycine buffer or citrate buffer solution with a pH of 2.5 to 4.0, or adding a large amount of citric acid to the reaction solution.

[0135] (5) Purification Step The "purification step" is a step of separating and purifying the antibody-substrate complex of interest from the mixture of antibody-substrate complex and other contaminants obtained after the enzymatic separation step. There are no limitations on the method for selectively separating and purifying the antibody-substrate complex from the reaction solution after the enzymatic separation step. Any method known in the art may be used. For example, the antibody-substrate complex can be isolated using chromatography or ultrafiltration. Generally, because the antibody and the MTG fusion differ in both molecular weight and isoelectric point, methods such as size exclusion chromatography based on molecular weight and ion exchange chromatography based on isoelectric point are effective.

[0136] Example 1: Preparation of MTG fusion product (Objective) To prepare an MTG fusion product of the present invention (Method) 1. Preparation of Pro(K10R / Y12A)MTG-(G4S)3-pG Pro(K10R / Y12A)MTG-(G4S)3-pG was prepared by fusing the antibody-binding protein Protein G(pG) (C2 domain) to the C-terminus of active ProMTG, Pro(K10R / Y12A)MTG, via the linker (G4S)3.

[0137] Plasmid pET22b (+)_Pro(K10R / Y12A)-MTG-(G4S)3-pZ encoding Pro(K10R / Y12A)-MTG-(G4S)3 Ca2+A vector DNA fragment was prepared by PCR using the template pET22b(+)_H6-pG2 with the Fw primer consisting of the nucleotide sequence shown in SEQ ID NO: 14 and the Rv primer consisting of the nucleotide sequence shown in SEQ ID NO: 15. The PCR reaction mixture consisted of 12.5 μL of PrimeSTAR® Max DNA Polymerase (Takara Bio Inc.), 0.75 μL each of 0.3 μM Fw / Rv primers, and 0.50 μL of template DNA, adjusted to 25 μL with MilliQ water. The PCR reaction conditions were (98°C for 10 seconds + 55°C for 5 seconds + 72°C for 35 seconds) x 35 cycles, followed by storage at 4°C. An insert DNA fragment was prepared using the template pET22b(+)_H6-pG2 encoding pG with the Fw primer consisting of the nucleotide sequence shown in SEQ ID NO: 16 and the Rv primer consisting of the nucleotide sequence shown in SEQ ID NO: 17 under the same conditions as the PCR described above.

[0138] After the PCR reaction, the vector DNA fragment and the insert DNA fragment were extracted and purified by standard methods, and the two fragments were ligated to construct the recombinant plasmid pET22b(+)Pro(K10R / Y12A)MTG-(G4S)3-pG.

[0139] Next, pET22b(+)Pro(K10R / Y12A)MTG-(G4S)3-pG was introduced into E. coli to obtain transformants, which were then cultured. 600 After the pH reached approximately 0.5, IPTG was added to a final concentration of 0.25 mM to induce expression. After overnight culture, the culture supernatant was collected and analyzed by HisTrap™. TM His-tag purification was performed using an FFcrude column (Cytiva). After purification, the yield and purity were confirmed by SDS-PAGE, and the product was purified using a HiLoad 16 / 600 Superdex column. TM Further purification was carried out using size exclusion chromatography (SEC) (Cytiva) using a 200 pg column to obtain the target protein.

[0140] 2. Preparation of pG-G4S-Pro(K10R / Y12A)MTG Next, the positions of Pro(K10R / Y12A)MTG and pG in the Pro(K10R / Y12A)MTG-(G4S)3-pG were swapped to prepare pG-G4S-Pro(K10R / Y12A)MTG, which was fused via the linker G4S. The basic procedure followed the method described above in "1. Preparation of Pro(K10R / Y12A)MTG-(G4S)3-pG." The primer pair used to prepare the vector DNA fragment consisted of an Fw primer consisting of the nucleotide sequence shown in SEQ ID NO: 18 and an Rv primer consisting of the nucleotide sequence shown in SEQ ID NO: 19. The primer pair used to prepare the insert DNA fragment consisted of an Fw primer consisting of the nucleotide sequence shown in SEQ ID NO: 20 and an Rv primer consisting of the nucleotide sequence shown in SEQ ID NO: 21.

[0141] 3. Pro(K10R / Y12A)MTG-(G4S)3-pZ Ca2+ Preparation of (ΔK) pG in the Pro(K10R / Y12A)MTG-(G4S)3-pG was converted to pZ Ca2+ and then further mutations were introduced to replace the lysine residue at position 28 with an asparagine residue (K28N) and the alanine residue at position 29 with a tryptophan residue (A29W), and all remaining lysine residues were replaced with arginine residues, resulting in Pro(K10R / Y12A)-MTG-(G4S)3-pZ. Ca2+ The basic procedure was the same as that described in "1. Preparation of Pro(K10R / Y12A)MTG-(G4S)3-pG" above. Ca2+ All lysine residues in the nucleotide sequence were replaced with arginine residues to prevent self-crosslinking. K28N allows K28 to bind to pZ. 2+ A29W is a mutation introduced to prevent glycosylation of N and improve stability.

[0142] 4. Preparation of Pro(K10R / Y12A)MTG-(G4S)3-pZ (ΔK, Alkaline stabilized) Pro(K10R / Y12A)-MTG-(G4S)3-pZ Ca2+Similar to Pro(K10R / Y12A)MTG-(G4S)3-pG (ΔK), Pro(K10R / Y12A)MTG-(G4S)3-pG (ΔK, Alkaline stabilized) was prepared by replacing pG in Pro(K10R / Y12A)MTG-(G4S)3-pG with pZ(Alkaline stabilized), an alkali-tolerant variant of pZ. Furthermore, all lysine residues in the pZ(Alkaline stabilized) sequence were replaced with arginine residues, resulting in Pro(K10R / Y12A)MTG-(G4S)3-pG (ΔK, Alkaline stabilized). The basic procedure was as described in "1. Preparation of Pro(K10R / Y12A)MTG-(G4S)3-pG" above. pZ (Alkaline stabilized) is a mutant form of pZ in which the N3A, N21A, and N23T mutations were introduced into pZ.

[0143] Example 2: Crosslinking reaction of drug model Q substrate to antibody using MTG fusion product (Purpose) Using each MTG fusion product prepared in Example 1, a crosslinking reaction of drug model Q substrate peptide to trastuzumab (IgG), an IgG antibody pharmaceutical, was carried out, and its activity was evaluated.

[0144] (Method) The drug model Q substrate peptides containing a glutamine residue as a reactive site were TAMRA-YPLQMRG-NH2, in which the peptide tag YPLQMRG shown in SEQ ID NO: 13, which has high MTG reactivity, was bound to the red fluorescent molecule TAMRA (5-carboxytetramethylrhodamine), and TAMRA-βAla-QG, in which βAla-QG was bound.

[0145] (1) Evaluation of Crosslinking Activity of Pro(K10R / Y12A)MTG-(G4S)3-pG and pG-G4S-Pro(K10R / Y12A)MTG The crosslinking activity of Pro(K10R / Y12A)MTG-(G4S)3-pG and pG-G4S-Pro(K10R / Y12A)MTG with Trastuzumab (IgG) and TAMRA-YPLQMRG-NH2 and TAMRA-βAla-QG was evaluated and compared. The reaction mixture consisted of 3.3 μM Trastuzumab (IgG), 200 μM TAMRA-YPLQMRG-NH2 or TAMRA-βAla-QG, and 1.25 μM of the MTG fusion protein prepared in Example 1 in 1x PBS (pH 7.4). The reaction mixture (total volume: 25 μL) was incubated at 37°C. After 30 minutes, N-ethylmaleimide (NEM) was added to a final concentration of 1 mM to stop the reaction. Subsequently, an equal volume of 2x Sample Buffer was added to the reaction mixture, and the mixture was heated at 98°C. The cross-linking activity of each MTG fusion protein was evaluated by SDS-PAGE and fluorescence imaging. Note that none of the Trastuzumab (IgG) used was deglycosylated.

[0146] (2) Pro(K10R / Y12A)MTG-(G4S)3-pZ Ca2+ Evaluation of cross-linking activity by Pro(K10R / Y12A)MTG-(G4S)3-pZ (ΔK, Alkaline stabilized) Ca2+The crosslinking activity of Trastuzumab (IgG) with TAMRA-YPLQMRG-NH2 and TAMRA-βAla-QG using (ΔK) and Pro(K10R / Y12A)MTG-(G4S)3-pZ(ΔK, alkaline stabilized) was also evaluated and compared in the same manner as in (1). The basic procedure was the same as in (1), but some conditions, such as composition and concentration, were different. Specifically, the reaction mixture consisted of 3.3 μM Trastuzumab (IgG), 200 μM TAMRA-YPLQMRG-NH2 or TAMRA-βAla-QG, 3.3 μM of the MTG fusion protein prepared in Example 1, and 10 mM Tris-HCl (pH 7.4) containing 500 μM CaCl2. The reaction mixture, total volume 10 μL, was incubated at 37°C. After 30 minutes, N-ethylmaleimide (NEM) was added to a final concentration of 1 mM to terminate the reaction. Subsequently, the reaction mixture was heat-treated at 98°C, and the cross-linking activity of each MTG fusion was evaluated by SDS-PAGE and fluorescent imaging.

[0147] (Results) (1) Cross-linking activity of Pro(K10R / Y12A)MTG-pG and pG-Pro(K10R / Y12A)MTG. The reaction results are shown in Figure 3. As shown in this figure, when the MTG fusions of the present invention, Pro(K10R / Y12A)MTG-pG and pG-Pro(K10R / Y12A)MTG, in which pG is fused to active MTG, were used to react the substrate molecule TAMRA-YPLQMRG, which contains a lysine residue, with the antibody drug Trastuzumab (IgG), strong fluorescence derived from TAMRA was observed in the band (49.16 kDa) derived from the IgG heavy chain. On the other hand, when Pro(K10R / Y12A)MTG, which is composed only of active MTG without pG fusion, was used, almost no fluorescence was observed in either the heavy or light chain. These results demonstrate that the MTG fusions of the present invention significantly improve the cross-linking activity of IgG.

[0148] Furthermore, cross-linking activity was confirmed even though the IgG used in this example had not been deglycosylated. Current methods for modifying IgG using MTG require deglycosylation of the IgG, which then cross-links the exposed Q295 of the IgG to a primary amine. However, it has been revealed that the MTG fusion protein of the present invention does not require deglycosylation of the antibody for antibody modification.

[0149] On the other hand, Pro(K10R / Y12A)MTG-pG and pG-Pro(K10R / Y12A)MTG also emitted fluorescence, suggesting that these MTG fusions undergo self-modification of their own lysine residues.

[0150] (2) Pro(K10R / Y12A)MTG-(G4S)3-pZ Ca2+ Crosslinking activity of Pro(K10R / Y12A)-MTG-(G4S)3-pZ (ΔK, Alkaline stabilized) The reaction results are shown in Figure 4. As shown in this figure, the MTG fusion construct Pro(K10R / Y12A)MTG-(G4S)3-pZ of the present invention, in which pG is fused to active MTG, Ca2+ (ΔK) and Pro(K10R / Y12A)MTG-(G4S)3-pZ Ca2+ When the substrate molecule TAMRA-YPLQMRG containing a lysine residue was reacted with the antibody drug trastuzumab (IgG) using (ΔK, alkaline stabilized), strong fluorescence from TAMRA was confirmed in both cases in the heavy chain of IgG. These results confirmed that not only pG but also mutant pZ has affinity for IgG and MTG activity.

[0151] On the other hand, similar to (1), it was suggested that automodification also occurred when these MTG fusions were used. Furthermore, Pro(K10R / Y12A)MTG-(G4S)3-pZ Ca2+ (ΔK) is the cofactor Ca 2+ The modification of the substrate molecule to the heavy chain of IgG occurs regardless of the presence or absence of Ca. 2+ Ca-dependent IgG binding capacity is lost. 2+These results suggest that the protein is capable of interacting with IgG regardless of the presence or absence of IgG.

[0152] Example 3: Identification of the modified position of the substrate molecule on an antibody using an MTG fusion compound (Objective) The binding position of the drug in IgG is crucial for the therapeutic effect of ADC. Therefore, the modification position of Trastuzumab (IgG) modified with TAMRA-YPLQMRG-NH2 by Pro(K10R / Y12A)MTG-(G4S)3-pG was identified by peptide mapping.

[0153] (Method) To identify the modification sites, unmodified and modified heavy chains were separated by reverse-phase HPLC under reducing conditions, digested into peptide fragments with trypsin, and then further separated by reverse-phase HPLC to obtain chromatogram patterns. The chromatogram patterns were compared, and the peaks specific to the modified heavy chains were analyzed by MALDI-TOF MS measurement to identify the modification sites.

[0154] (1) Q-substrate modification of antibody with Pro(K109R / Y11A)MTG-(G4S)3-pG. Q-substrate modification of IgG with Pro(K10R / Y12A)MTG-(G4S)3-pG was performed under the following conditions. The reaction mixture consisted of 6.6 μM Trastuzumab (IgG), 100 μM TAMRA-YPLQMRG-NH2, and 6.6 μM Pro(K10R / Y12A)MTG-(G4S)3-pG in 10 mM Tris (pH 7.4). The reaction mixture was incubated at 37°C for 2 hours in a total volume of 100 μL. NEM was then added to a final concentration of 1 mM to terminate the crosslinking reaction with MTG.

[0155] Next, 100 μL of 6 M guanidine hydrochloride (100 mM ammonium bicarbonate) was added to 100 μL of the reaction mixture, and DTT was added to a final concentration of 20 mM. The reduction reaction was carried out at 60°C for 1 hour. IAA was then added to a final concentration of 80 mM, and the alkylation reaction was carried out at room temperature for 1 hour in the dark. The reduced and alkylated sample was subjected to reverse-phase HPLC on a COSMOSIL 5Ph-AR-300 column (Nakarai Tesque), and the Q substrate-modified heavy chain and unmodified heavy chain were purified and recovered. Purification was carried out under the conditions listed in Table 1, using solvents A and B and eluting with an acetonitrile gradient.

[0156]

[0157] The recovered Q substrate-modified heavy chain and unmodified heavy chain were powdered by freeze-drying.

[0158] Next, 120 μg of the purified and recovered Q substrate-modified heavy chain was dissolved in 100 μL of 8 M urea (100 mM ammonium bicarbonate). 100 μL of 37.5 μg / mL trypsin solution (100 mM ammonium bicarbonate) was added, and the digestion reaction was carried out at 37°C for 2 hours. Then, 3.75 μL of 1.0 mg / mL trypsin solution was added, and the digestion reaction was carried out again at 37°C for 2 hours. Finally, 50 μL of 0.1% TFA solution was added to stop the reaction. The same procedure was carried out with unmodified heavy chain, which was used as a control.

[0159] The prepared Q substrate-modified heavy chain and unmodified heavy chain fragment peptides were analyzed by reverse-phase HPLC using a COSMOSIL 5C18-AR-300 column. Purification was performed using solvents A and B with an acetonitrile gradient elution under the conditions shown in Table 2. All peaks that appeared were collected and used in subsequent experiments.

[0160]

[0161] Next, 2 μL of sample from each peak in the chromatogram was spotted onto an MTP384 target plate ground steel BC (Thermo Fisher Scientific), and 2 μL of saturated CHCA solution was spotted at the same position, mixed, and then allowed to air-dry. After air-drying, MALDI-TOF MS measurement was performed using an autoflex® maX (Bruker) to obtain the molecular weight of each peak. Peptide mapping was performed by comparing the obtained values ​​with the molecular weight of peptides generated by trypsin treatment from the heavy chain sequence of Trastuzumab, and the modification site of the Q substrate was identified. In addition, N-terminal analysis of peptide fragments derived from the modification site was performed (commissioned to Hokkaido System Science Co., Ltd.) to confirm the results.

[0162] (Results) (1) Q substrate modification reaction of antibody with Pro(K10R / Y12A)MTG-(G4S)3-pG The results are shown in Figures 5 and 6. Figure 5 shows chromatograms of the unmodified and Q substrate-modified heavy chains by reversed-phase HPLC, and Figure 6 shows the results of reversed-phase HPLC of the unmodified and Q substrate-modified heavy chain fragment peptides.

[0163] Figure 5 suggests that the separation of unmodified heavy chains and Q substrate-modified heavy chains was successful. Among the fractions in the chromatogram in Figure 5, the fraction containing the peak likely derived from the Q substrate-modified heavy chain was red due to TAMRA. Furthermore, in the chromatogram shown in Figure 6, where the Q substrate-modified heavy chain was treated with trypsin, a new peak was present around 37 minutes (arrow in Figure 6). When this peak was fractionated, the eluate was red, suggesting that it was a peptide from the TAMRA modification site.

[0164] Furthermore, peptide mapping by MALDI-TOF MS analysis, performed to identify the peptides in each peak, successfully identified approximately 95% of the heavy chain sequence of Trastuzumab (IgG) (not shown). The peak specific to the Q substrate-modified heavy chain fragment peptide shown in Figure 6 was determined to be a peptide with a molecular weight of 2097.008 from MALDI-TOF MS analysis. The molecular weight of the sequence at the modification site was calculated from this value, resulting in a molecular weight of 895.698 (m / z), which corresponds to the heavy chain digestion fragment sequence YADSVK. 65 The molecular weight of TAMRA-YPLQMRG-NH2 was approximately equal to the molecular weight of 894.98 of GR (SEQ ID NO: 22). Therefore, the modification site of TAMRA-YPLQMRG-NH2 was the lysine residue at position 65 of the heavy chain (K 65 ) was strongly suggested.

[0165] Furthermore, as a result of N-terminal sequence analysis of the above Q substrate-modified heavy chain fragment peptide, it was found that the sequence from the N-terminus was YADSV (SEQ ID NO: 23). This indicated that the sequence of the modification site was YADSVK, as predicted by the above modification sequence. 65 GR (SEQ ID NO: 22), and the modification position of TAMRA-YPLQMRG-NH2 was K 65 was identified as follows.

[0166] Example 4: Preparation of modified MTG fusion protein (Objective) A modified MTG fusion protein is prepared by introducing a mutation into the antibody binding domain pG of the MTG fusion protein.

[0167] (Method) The results of Example 2 revealed that the MTG fusions of the present invention prepared in Example 1 all have strong activity to efficiently cross-link substrate molecules to specific amino acid residues in the heavy chain of IgG. However, new problems were also revealed, such as the formation of aggregates between the MTG fusions and antibodies, and the self-modification of lysine residues of the MTG fusions by the substrate molecules.

[0168] We predicted that aggregation formation would be promoted by binding of wild-type pG to the antibody Fc region and Fab region G, and that this was due to the presence of MTG-reactive lysine residues in the pG sequence. Therefore, we constructed modified MTG fusion constructs containing pG mutants that had lost either the antibody-binding ability by introducing mutations into the Fc-binding region or the Fab-binding region of wild-type pG.

[0169] 1. Preparation of Pro(K10R / Y12A)MTG-(G4S)3-pG (Fab-ΔKQ) All of the lysine residues and arginine residues present in the Fab-binding region of the pG domain of Pro(K10R / Y12A)MTG-(G4S)3-pG prepared in Example 1 were substituted with arginine residues and asparagine residues, respectively, to prepare Pro(K10R / Y12A)MTG-(G4S)3-pG (Fab-ΔKQ), in which the Fab-binding ability of the Fab-binding region was lost.

[0170] A vector DNA fragment was prepared by PCR using the plasmid pET22b(+)_Pro(K10R / Y12A)MTG-(G4S)3-pG encoding Pro(K10R / Y12A)MTG-(G4S)3 as a template and an Fw primer consisting of the nucleotide sequence shown in SEQ ID NO: 24 and an Rv primer consisting of the nucleotide sequence shown in SEQ ID NO: 25.

[0171] The PCR reaction mixture consisted of 12.5 μL of PrimeSTAR Max DNA Polymerase (Takara Bio), 0.75 μL each of 0.3 μM Fw / Rv primers, and 0.50 μL of template DNA, adjusted to 25 μL with MilliQ water. The PCR conditions were (98°C for 10 seconds, 55°C for 5 seconds, and 72°C for 35 seconds) x 35 cycles, followed by storage at 4°C. The insert DNA fragment was prepared by PCR using pG(Fab-ΔKQ), synthesized by Integrated DNA Technologies, Inc., as a template, with the Fw primer consisting of the nucleotide sequence shown in SEQ ID NO: 26 and the Rv primer consisting of the nucleotide sequence shown in SEQ ID NO: 27. The PCR conditions were (98°C for 10 seconds, 55°C for 5 seconds, and 72°C for 5 seconds) x 35 cycles, followed by storage at 4°C.

[0172] After the PCR reaction, the vector DNA fragment and the insert DNA fragment were extracted and purified by standard methods, and the two fragments were ligated to construct the recombinant plasmid pET22b(+)_Pro(K10R / Y12A)MTG-(G4S)3-pG(Fab-ΔKQ).

[0173] Next, pET22b(+)_Pro(K10R / Y12A)MTG-(G4S)3-pG(Fab-ΔKQ) was introduced into E. coli to obtain transformants, which were then cultured and induced by adding IPTG to a final concentration of 0.1 mM. After overnight culture, the culture supernatant was collected and analyzed using HisTrap TM His-tag purification was performed using an FF crude column (Cytiva). After purification, the yield and purity were confirmed by SDS-PAGE, and the product was purified using a HiLoad 16 / 600 Superdex column. TM Further purification was carried out using size exclusion chromatography (SEC) (Cytiva) using a 200 pg column to obtain the target protein.

[0174] 2. Preparation of pG(Fab-ΔKQ)-G4S-Pro(K10R / Y12A)MTG All of the lysine residues and arginine residues present in the Fab-binding region of the pG domain of pG-G4S-Pro(K10R / Y12A)MTG prepared in Example 1 were substituted with arginine residues and asparagine residues, respectively, to prepare pG(Fab-ΔKQ)-G4S-Pro(K10R / Y12A)MTG in which the Fab-binding ability of the Fab-binding region was lost.

[0175] A vector DNA fragment was generated by PCR using the plasmid pET22b(+)_pG-G4S-Pro(K10R / Y12A)-MTG encoding G4S-Pro(K10R / Y12A)-MTG as a template, with the Fw primer consisting of the nucleotide sequence shown in SEQ ID NO: 28 and the Rv primer consisting of the nucleotide sequence shown in SEQ ID NO: 29. The PCR reaction mixture consisted of 12.5 μL of PrimeSTAR Max DNA Polymerase (Takara Bio Inc.), 0.75 μL each of 0.3 μM Fw and Rv primers, and 0.50 μL of template DNA, adjusted to 25 μL with MilliQ water. The PCR reaction conditions were 35 cycles of (98°C for 10 seconds, 55°C for 5 seconds, and 72°C for 35 seconds), followed by storage at 4°C. An insert DNA fragment was prepared by PCR using pG(Fab-ΔKQ), synthesized by Integrated DNA Technologies Co., Ltd., as a template, an Fw primer consisting of the nucleotide sequence shown in SEQ ID NO: 30, and an Rv primer consisting of the nucleotide sequence shown in SEQ ID NO: 31. The PCR reaction conditions were (98°C for 10 seconds + 55°C for 5 seconds + 72°C for 5 seconds) x 35 cycles, followed by storage at 4°C.

[0176] After the PCR reaction, the vector DNA fragment and the insert DNA fragment were extracted and purified by standard methods, and the two fragments were ligated to construct the recombinant plasmid pET22b(+)_pG(Fab-ΔKQ)-G4S-Pro(K10R / Y12A)-MTG.

[0177] Next, pET22b(+)_pG(Fab-ΔKQ)-G4S-Pro(K10R / Y12A)-MTG was introduced into E. coli to obtain transformants. After culturing the transformants, IPTG was added to a final concentration of 0.1 mM to induce expression. After overnight culture, the culture supernatant was collected and analyzed using HisTrap®. TM His-tag purification was performed using an FF crude column (Cytiva). After purification, the yield and purity were confirmed by SDS-PAGE, and the product was purified using a HiLoad 16 / 600 Superdex column. TMFurther purification was carried out using size exclusion chromatography (SEC) (Cytiva) using a 200 pg column to obtain the target protein.

[0178] <Example 5: Evaluation of aggregation formation and cross-linking activity between modified MTG fusion protein and antibody> (Purpose) To evaluate aggregation with antibody in the modified MTG fusion protein Pro(K10R / Y12A)MTG-(G4S)3-pG(Fab-ΔKQ) prepared in Example 4, and to verify whether the use of pG specific to one of the Fab regions eliminates aggregation formation that occurs when Pro(K10R / Y12A)MTG-(G4S)3-pG is mixed with antibody.

[0179] Furthermore, to examine whether the use of pG(Fab-ΔKQ), which specifically binds to the Fab region of pG and in which all lysine and glutamine residues have been replaced, alters self-labeling, we evaluated the crosslinking activity of Pro(K10R / Y12A)MTG-(G4S)3-pG or Pro(K10R / Y12A)MTG-(G4S)3-pG(Fab-ΔKQ) toward an antibody (Herceptin) and a drug model Q substrate peptide (TAMRA-YPLQMRG-NH2).

[0180] (Method) Herceptin (IgG) and MTG fusion protein (Pro(K10R / Y12A)MTG-(G4S)3-pG or Pro(K10R / Y12A)MTG-(G4S)3-pG(Fab-ΔKQ)) were mixed in 1x PBS (pH 7.4) and incubated at 37°C for 1 hour. OD was then measured using a Nanodrop ultra-microspectrophotometer (Thermo Fisher Scientific). 600 The agglutination with the antibody was evaluated by measuring turbidity.

[0181] Next, Herceptin (IgG), MTG fusions (Pro(K10R / Y12A)MTG-(G4S)3-pG or Pro(K10R / Y12A)MTG-(G4S)3-pG (Fab-ΔKQ)), and TAMRA-YPLQMRG-NH2 were mixed in 1x PBS (pH 7.4) to assess the cross-linking activity of the MTG fusions. After the antibody and MTG fusions were mixed and brought into close proximity, TAMRA-YPLQMRG-NH2 was added and incubated at 37°C for 1 hour. The reaction mixture was mixed with an equal volume of 2x SDS-PAGE Sample Buffer and heated at 98°C for 30 minutes. SDS-PAGE was then performed, and the cross-linking activity of each MTG fusion was assessed by fluorescence imaging.

[0182] (Results) Figure 7 shows the results of the aggregate formation evaluation, and Figure 8 shows the results of the cross-linking activity evaluation. Figure 7 shows that the OD of the positive control Pro(K10R / Y12A)MTG-(G4S)3-pG, which forms aggregates when mixed with the antibody Herceptin, was 0.1. 600 In contrast, Pro(K10R / Y12A)MTG-(G4S)3-pG(Fab-ΔKQ) 600 was significantly lower, demonstrating that introducing mutations by amino acid substitution into the Fc region or Fab region of the pG site eliminated the aggregation that occurred when the MTG fusion product was mixed with the antibody.

[0183] In addition, the positive control Pro(K10R / Y12A)MTG-(G4S)3-pG itself was self-labeled with TAMRA-YPLQMRG-NH2 (Fig. 3). However, in Pro(K10R / Y12A)MTG-(G4S)3-pG (Fab-ΔKQ), in which all lysine residues in pG were substituted, such self-labeling was completely inhibited (Fig. 8). This result revealed that the reactive site for self-labeling was the lysine residue in pG.

[0184] Example 6: Identification of modification positions of substrate molecules on antibodies using modified MTG fusion products (Purpose) The modification positions of Trastuzumab (IgG) modified with TAMRA-YPLQMRG-NH2 using the modified MTG fusion products (Pro(K10R / Y12A)MTG-(G4S)3-pG and pG(Fab-ΔKQ)-G4S-Pro(K10R / Y12A)MTG) prepared in Example 4 were identified by peptide mapping in the same manner as in Example 3.

[0185] (Method) The basic operation was in accordance with the method described in Example 3.

[0186] (Results) Pro(K10R / Y12A)MTG-(G4S)3-pG(Fab-ΔKQ) also showed a peak similar to that of Pro(K10R / Y12A)MTG-(G4S)3-pG, indicating that K65 was modified (not shown). HPLC analysis of peptide fragments of the dye-labeled modified antibody showed that Pro(K10R / Y12)MTG-(G4S)3-pG(Fab-ΔKQ) showed the same K65 modification as Pro(K10R / Y12A)MTG-(G4S)3-pG. 65 Modification of the Q substrate to

[0187] On the other hand, as shown in Figure 9, HPLC peptide mapping was performed to identify the modification site of pG(Fab-ΔKQ)-G4S-Pro(K10R / Y12A)MTG. The peak derived from K65 detected in Pro(K10R / Y12A)MTG-pG(Fab-ΔKQ) (the peak indicated by the arrow in the figure) disappeared, and two new peaks (indicated by the arrowheads in the figure) appeared. Analysis of these peaks by MALDI-TOF revealed that the m / z of the first arrowhead peak was 3726.820, which approximately corresponds to the molecular weight of TAMRA-YPLQMRG-NH2 bound to the peptide from serine 222 to leucine 245 at the N-terminus of the IgG heavy chain. The m / z of the second arrowhead peak was 4536.508, which approximately corresponds to the molecular weight of TAMRA-YPLQMRG-NH2 bound to the peptide from serine 222 to lysine 251 at the N-terminus of the IgG heavy chain. Furthermore, the results of N-terminal sequence analysis of both peptides were the same, with the N-terminus being SXDXT. It was suggested that the second X was an alkylated cysteine ​​and the fourth X was a K modified with TAMRA-YPLQMRG-NH2 (SEQ ID NO: 36). This suggested that the lysine residue at position 225 of the IgG heavy chain (K 225 These results indicate that pG(Fab-ΔKQ)-G4S-Pro(K10R / Y12A)MTG can be modified at the lysine residue at position 225, making it possible to control the modification position of the antibody depending on the type of MTG fusion molecule. 225 is located in the hinge region that connects the heavy chains of the Fc and Fab of an antibody and is not involved in antigen binding ability.

[0188] <Example 7: Antigen binding activity of fluorescently modified antibody prepared using modified MTG fusion product> (Purpose) To verify that the antibody-substrate complex consisting of Herceptin (IgG) fluorescently modified with the modified MTG fusion product prepared in Example 4 maintains its antigen binding activity.

[0189] (Method) SK-BR-3 cells, which have HER2, the target molecule of Herceptin, on the cell membrane surface, were treated with a fluorescently labeled antibody and observed by CLSM.

[0190] (1) Preparation of SK-BR-3 cells. SK-BR-3 cells were obtained from ATCC. 10 mL of McCoy's 5A (10% FBS, 1x Anti-Anti) medium was placed in a dish, and 5x10 cells were cultured. 5 SK-BR-3 cells were seeded at 100 cells / well and cultured at 37°C under 5% CO for 3 to 4 days. After culture, cell growth was confirmed and the cells were passaged as necessary.

[0191] (2) Preparation of Fluorescently Modified Antibody The modified MTG fusion proteins (Pro(K10R / Y12A)MTG-(G4S)3-pG and pG(Fab-ΔKQ)-G4S-Pro(K10R / Y12A)MTG) prepared in Example 4 were used to fluorescein-modify the K of Herceptin (IgG) with TAMRA-YPLQMRG-NH2. 65 and K. 225 Fluorescently modified antibodies were prepared by modifying each of the above antibodies with fluorescent dyes. The basic procedure was the same as that described in Example 4.

[0192] (3) Confirmation of binding of fluorescently labeled antibodies to SK-BR-3 cells. 1.0 x 10 cells were plated in a 4-well dish using McCoy's 5A (10% FBS, 1x Anti-Anti) medium. 4 Cells were seeded at 1000 cells / well and incubated overnight in a CO2 incubator to allow the cells to adhere to the bottom. The plate was washed once with Opti-MEM. Fluorescently labeled antibodies were then added to a final concentration of 10 μg / mL, and the plate was incubated for 1 hour in a CO2 incubator. After washing with Opti-MEM, the plate was fixed with 4% paraformaldehyde fixative and allowed to stand for 10 minutes to fix the cells. After washing with Opti-MEM, the plate was subjected to CLSM observation.

[0193] (Results) The results are shown in Figure 10. Figure 10 is a CLSM image of K 225 F / f and K 65 Fluorescence was observed on the surface of the SK-BR-3 cell membrane only in G / g, where an antibody modified with a fluorescent substrate was added, confirming that the fluorescently modified antibody bound to SK-BR-3 (f and g in the figure). These results also demonstrated that the fluorescently modified antibody maintained its antigen-binding ability.

[0194] Example 8: Evaluation of cross-linking activity of modified MTG fusion proteins depending on the type of linker. (Purpose) In modified MTG fusion proteins, the cross-linking activity depending on the type of linker connecting the cross-linking catalytic domain and the antibody-binding domain is evaluated based on the substrate modification rate for the antibody.

[0195] (Method) The modified MTG fusion protein used in this example was pG(Fab-ΔKQ)-(linker)-Pro(K10R / Y12A)MTG, which has an antibody-binding domain of pG(Fab-ΔKQ), a bridging catalytic domain of Pro(K10R / Y12A)MTG, and the domains are linked by a linker.

[0196] The basic method for preparing the modified MTG fusion protein was similar to that described in "2. Preparation of pG(Fab-ΔKQ)-G4S-Pro(K10R / Y12A)MTG" in Example 4. However, in this example, various types of linkers were used. In this example, a G4S linker, a (G4S)3 linker, a polyproline linker, an IgA linker, and an HA tag linker were used.

[0197] The crosslinking activity of each pG(Fab-ΔKQ)-(linker)-Pro(K10R / Y12A)MTG was evaluated based on the crosslinking activity of the drug model Q substrate peptide (TAMRA-YPLQMRG-NH2) to the antibody (Herceptin) described in Example 5. The basic method followed the method described in Example 5. The amount of substrate-modified antibody was calculated as the modification rate, assuming that the total amount of antibody used for modification was 100%.

[0198] (Results) The results are shown in Table 3.

[0199] The above results suggest that the cross-linking activity of the modified MTG fusion protein of the present invention varies depending on the type of linker connecting the cross-linking catalytic domain and the antibody-binding domain.

[0200] The modified MTG fusions using the G4S linker and (G4S)3 linker used in the above examples were able to modify half of the antibody with the substrate, but the polyproline linker and IgA linker only modified 30% or less of the antibody. On the other hand, when the HAtag linker was used, a high modification rate of 80% was observed, demonstrating a significant improvement in the cross-linking activity of the modified MTG fusions.

[0201] Example 9: Evaluation of cross-linking activity of modified MTG fusion protein using mutant HAtag linker (Objective) The results of Example 8 revealed that the modified MTG fusion protein pG(Fab-ΔKQ)-HAtag-Pro(K10R / Y12A)MTG containing the HAtag linker exhibited a significantly higher modification rate than other linkers. This was suggested to be due to the fact that only the HAtag linker contains two negatively charged aspartic acid residues, and therefore the charge of the linker affects the cross-linking activity.

[0202] Therefore, in this Example, we used a mutant HAtag (mHAtag) linker in which an additional charged amino acid was added to the HAtag linker to examine the change in crosslinking activity of the modified MTG fusion protein pG(Fab-ΔKQ)-mHAtag-Pro(K10R / Y12A)MTG.

[0203] (Method) The mutant HAtag linkers used were the Y1R HAtag linker, in which the tyrosine residue at position 1 of the HAtag linker was substituted with the positively charged amino acid arginine, and the Y1D / P2D HAtag linker, in which the tyrosine residue at position 1 and the proline residue at position 2 of the HAtag linker were substituted with the negatively charged amino acid aspartic acid. These linkers were prepared by introducing mutations into predetermined positions of the nucleic acid encoding the HAtag linker using synthetic primers. The modified MTG fusion construct pG(Fab-ΔKQ)-mHAtag-Pro(K10R / Y12A)MTG was prepared according to the method described in Example 4, "2. Preparation of pG(Fab-ΔKQ)-G4S-Pro(K10R / Y12A)MTG."

[0204] The cross-linking activity of pG(Fab-ΔKQ)-mHAtag-Pro(K10R / Y12A)MTG was evaluated based on the cross-linking activity described in Example 5. As in Example 8, the basic method was the same as that described in Example 5.

[0205] (Results) The results are shown in Table 4.

[0206] The above results indicate that the modified MTG fusion using the Y1R-HA tag, which contains an additional positively charged arginine, exhibited a higher modification rate than the modified MTG fusions using linkers other than the HA tag listed in Table 3, but a lower modification rate than the modified MTG fusion using the original HA tag. On the other hand, the modified MTG fusion using the Y1D / P2D HA tag, which contains an additional negatively charged aspartic acid, exhibited a higher modification rate than the modified MTG fusion using the original HA tag. These results demonstrate that the charge of the linker affects the cross-linking activity of the modified MTG fusions containing linkers, with negatively charged amino acid residues promoting cross-linking activity and positively charged amino acid residues decreasing it. These results suggest that the modified MTG fusions using linkers containing more negatively charged amino acid residues exhibit higher cross-linking activity and a higher substrate modification rate.

[0207] Example 10: Preparation of ADC (Objective) In Example 2, TAMRA-YPLQMRG-NH2 was used as a drug model Q substrate for the substrate molecule. In this example, an actual drug is used to crosslink an antibody with a modified MTG fusion protein, prepare an ADC, and evaluate its efficacy, i.e., cytotoxicity and cell specificity.

[0208] (Method) The synthetic anticancer drug MMAE (monomethyl auristatin E) was used as the drug. MMAE was labeled with a PEG azide reagent, resulting in Azido-PEG4-Val-Cit PAB-MMAE, which was used to prepare an ADC. The peptide tag used was DBCO-YPLQMRG-NH2, in which DBCO, a click reaction element, was conjugated to YPLQMRG (SEQ ID NO: 13). The antibody used was Herceptin, as in Example 2. In this example, instead of directly crosslinking the peptide tag YPLQMRG bound to a substrate molecule (TAMRA) to Herceptin using the crosslinking activity of a modified MTG fusion as in Example 2, the peptide tag containing DBCO (DBCO-YPLQMRG-NH2) was first crosslinked to Herceptin using MTG activity, and then the DBCO peptide tag was conjugated to the azide group of Azido-PEG4-Val-Cit PAB-MMAE via a click reaction.

[0209] (1) Preparation of DBCO-modified Herceptin (DBCO(K65)-Herceptin) The reaction mixture was a mixture of Herceptin, DBCO-YPLQMRG-NH2, and pG(Fab-ΔKQ)-HAtag-Pro(K10R / Y12A)MTG in Tris-HCl (pH 8.0). After incubation at 37°C for 120 minutes, 0.1 M citrate buffer (pH 3.0) was added to terminate the MTG reaction and inactivate the antibody binding of pG.

[0210] The entire volume was then loaded onto a HiFliQ S-type column (Protein Ark) and purified by cation exchange chromatography. 100 μL of 1 M Tris-HCl (pH 8.0) was added to each fraction for neutralization, and only the DBCO(K65)-Herceptin fraction was collected.

[0211] (2) Preparation of MMAE(K65)-Herceptin by Click Reaction Azido-PEG4-Val-Cit-PAB-MMAE was added to DBCO(K65)-Herceptin in 1x PBS (pH 7.4) to final concentrations of 1 μM and 50 μM, respectively, and the mixture was allowed to stand at 37°C for 60 minutes to react, yielding MMAE(K65)-Herceptin, an ADC in which Herceptin and MMAE are linked.

[0212] (3) Cytotoxicity of MMAE(K65)-Herceptin SK-BR-3 cells, which possess HER2, the target molecule of Herceptin, on their cell membrane surface, and MDA-MB-231 cells, which do not possess HER2 on their cell membrane surface, were seeded at 5000 cells / well in a 96-well plate and incubated at 37°C under 5% CO2 for 24 hours. The medium used for SK-BR-3 cells was McCoy's 5A, non-heat-treated FBS, and 1% antibiotic-antimycotic. The medium used for MDA-MB-231 cells was DMEM (high glucose, pyruvate), non-heat-treated FBS, and 1% antibiotic-antimycotic.

[0213] Azido-PEG4-Val-Cit-PAB-MMAE, unmodified Herceptin + Azido-PEG4-Val-Cit-PAB-MMAE, and MMAE(K65)-Herceptin were added to each cell culture medium to final concentrations of 50 nM, 10 nM, 5 nM, 1 nM, 0.5 nM, 0.1 nM, 50 pM, 10 pM, 5 pM, 1 pM, 0.5 pM, and 0.1 pM, and the cells were incubated at 37°C under 5% CO2 for 72 hours.

[0214] 20 μL of Cell Counting Kit-8 (Dojindo Laboratories) was added to each well, and the plate was incubated at 37° C. under 5% CO 2 for 4 hours, after which the absorbance at 450 nm was measured using a plate reader.

[0215] The cell viability was calculated using the following formula: Cell viability (%) = [(As - Ab) / (Ac - Ab)] x 100 As: Sample absorbance (sample + Cell Counting Kit-8) Ac: Negative control absorbance (cells + Cell Counting Kit-8 / no sample) Ab: Blank absorbance (medium + Cell Counting Kit-8 / no cells)

[0216] The IC50 was calculated by plotting the sample concentration on the horizontal axis against the cell viability on the vertical axis using the four-parameter logistic regression (4PL) method. The graph was created using GainData ELISA data analysis (Arigo Biolaborators).

[0217] (Results) The IC50 results are shown in Table 5.

[0218] The IC50 results showed that the ADC MMAE(K65)-Herceptin exhibited a significantly high efficacy of 0.097 nM (97 pM) in SK-BR-3 cells, which possess HER2, the target molecule of Herceptin, on their cell membrane surface. The IC50 values ​​of other ADCs, such as trastuzumab-MMAE, against SK-BR-3 cells have been reported to be 21.7 pM (Dennler P., et al., 2014, Bioconjugate Chem., 25(3):569-578) or 120 pM (Hadjabdelhafid-Parisien A., et al., 2022, RSC Adv., 12:33510-33515). These results demonstrate that the ADCs prepared using the modified MTG fusion compounds of the present invention exhibit efficacy comparable to that of known ADCs.

[0219] On the other hand, MMAE(K65)-Herceptin showed low cytotoxicity in MDA-MB-231 cells that lack HER2, the target molecule of Herceptin, demonstrating the antigen specificity of the ADC produced using the modified MTG fusion protein of the present invention.All publications, patents, and patent applications cited herein are incorporated herein by reference in their entirety.

Claims

1. A microbial transglutaminase fusion comprising an activated microbial transglutaminase precursor and an antibody-binding protein, wherein the activated microbial transglutaminase precursor comprises a mutant propeptide region in which at least one tyrosine residue and a lysine residue, at least one asparagine residue and a lysine residue, or at least one asparagine residue, at least one tyrosine residue and a lysine residue in the propeptide region of the microbial transglutaminase precursor are substituted with other amino acid residues.

2. A microbial transglutaminase fusion according to claim 1, comprising the active microbial transglutaminase precursor on the N-terminus and the antibody-binding protein on the C-terminus.

3. A microbial transglutaminase fusion according to claim 1, comprising the active microbial transglutaminase precursor on the C-terminus and the antibody-binding protein on the N-terminus.

4. A microbial transglutaminase fusion protein according to any one of claims 1 to 3, wherein the antibody-binding protein is a mutant antibody-binding protein.

5. The microbial transglutaminase fusion protein according to claim 4, wherein the mutant antibody-binding protein is a Fab-binding protein G that has lost the ability to bind to Fc in IgG.

6. The microbial transglutaminase fusion protein according to claim 4, wherein the mutant antibody-binding protein is Fc-binding protein G or Fc-binding protein A that has lost the ability to bind to Fab in IgG.

7. A microbial transglutaminase fusion according to any one of claims 1 to 6, in which the activated microbial transglutaminase precursor and the antibody-binding protein are fused via a linker consisting of a peptide chain.

8. A nucleic acid encoding a microbial transglutaminase fusion protein according to any one of claims 1 to 7.

9. A method for producing a microbial transglutaminase fusion, comprising: a mutation introduction step of introducing mutations into codons encoding at least one tyrosine residue and a lysine residue, at least one asparagine residue and a lysine residue, or at least one asparagine residue, at least one tyrosine residue and a lysine residue in the propeptide region of a nucleic acid fragment encoding a microbial transglutaminase precursor, by substituting them with other amino acid residues; a ligation step of ligating the nucleic acid fragment encoding the microbial transglutaminase precursor with a gene encoding an antibody-binding protein to prepare a transglutaminase fusion gene encoding a microbial transglutaminase fusion; and an expression step of expressing the transglutaminase fusion gene in a host cell.

10. An antibody modifying agent which comprises the microbial transglutaminase fusion protein according to any one of claims 1 to 7 and crosslinks a substrate molecule containing a glutamine residue to an antibody.

11. An antibody modifying agent comprising the microbial transglutaminase fusion protein according to claim 2, which crosslinks a substrate molecule containing a glutamine residue to the lysine residue at position 65 of an antibody.

12. An antibody modifying agent comprising the microbial transglutaminase fusion protein according to claim 3, which crosslinks a substrate molecule containing a glutamine residue to the lysine residue at position 225 of an antibody.

13. The antibody modifying agent of claim 11 or 12, wherein the substrate molecule comprises an azide group or a cycloalkynyl group.

14. A method for producing an antibody-substrate complex, comprising: an antibody binding step of mixing an antibody and an antibody modifying agent according to any one of claims 10 to 12, and binding a microbial transglutaminase fusion contained in the antibody modifying agent to the antibody to prepare an antibody-enzyme complex; a cross-linking step of mixing the antibody-enzyme complex and a substrate molecule containing a glutamine residue, and cross-linking the substrate molecule to the antibody to prepare an enzyme-antibody substrate complex; and an enzyme separation step of separating the microbial transglutaminase fusion from the enzyme-antibody substrate complex.

15. An antibody-substrate complex in which a substrate molecule is cross-linked to the lysine residue at position 65 of the IgG heavy chain.

16. An antibody-substrate complex in which a substrate molecule is cross-linked to the lysine residue at position 225 of the IgG heavy chain.

Citation Information

Patent Citations

  • Enzyme substrate for labeling of protein

    WO2010002042A1

  • Recombinant protein having transglutaminase activity

    WO2018004014A1

Cited By

  • Method for producing (antibody fragment)-substrate conjugate

    WO2026005034A1

  • Transglutaminase conjugate, antibody modifier containing same, and method for producing antibody-drug complex using transglutaminase conjugate

    WO2026075204A1